[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"_public_publisher_byId_11a0ef05-7ef5-47cf-8020-7b1fc64e85b5":3,"_public_publication_all{\"sortAscending\":false,\"sortField\":\"updateTime\",\"page\":0,\"size\":10,\"facet\":true,\"searchKey\":\"publisherId:11a0ef05-7ef5-47cf-8020-7b1fc64e85b5,\"}":167},{"code":4,"data":5,"meta":20},"SUCCESS",{"id":6,"createTime":7,"updateTime":8,"relativeEntities":9,"slug":10,"properties":11,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":22,"manageAffiliations":29,"indexDatabases":45,"url":20,"thumbnailPath":20,"statistic":80,"gsStatistic":20,"type":20,"analyzePriority":20},"11a0ef05-7ef5-47cf-8020-7b1fc64e85b5","2024-04-19T10:46:41.012+00:00","2025-11-21T10:05:06.970+00:00",[],"Springer-Science-and-Business-Media-LLC",{"issn":12,"title":14,"eissn":16},{"VOID":13},"1092-8464",{"EN":15},"Springer Science and Business Media LLC",{"VOID":17},"1534-3189","PUBLISHER","PENDING",null,0,[23],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":25,"label":26,"description":28,"parentId":20,"standard":20,"scholarHubFieldId":20},"2e748c70-3f53-41a9-99c9-1e3e45a3dc6d",[],{"EN":27},"Cardiology and Cardiovascular Medicine",{},[30,38],{"id":31,"createTime":20,"updateTime":20,"relativeEntities":32,"slug":20,"properties":33,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":36,"statistic":20},"8e7fce10-23c9-4f81-8998-abcf28ea16a0",[],{"title":34},{"EN":35},"Springer Nature",[37],"9a7c7208-b28a-42c2-a634-5a7f90eee3ab",{"id":39,"createTime":20,"updateTime":20,"relativeEntities":40,"slug":20,"properties":41,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":44,"statistic":20},"5179c8e6-7c4d-4a06-b5c2-78395a602acc",[],{"title":42},{"EN":43},"Current Science, Inc.",[],[46,63],{"id":47,"indexDatabase":48,"url":58,"indexYears":59,"academicFieldIds":60,"indexDatabaseRanking":62},"3da2aacf-ce73-4009-810f-ce250754fb88",{"id":49,"createTime":20,"updateTime":20,"relativeEntities":50,"label":51,"description":53,"key":55,"publicationTags":56,"standard":20},"3c7051d4-eb7d-4c57-a56b-36fc74c5d1e9",[],{"EN":52,"VI":52},"Scopus - Elsevier",{"EN":52,"VI":54},"Cơ sở dữ liệu Scopus thuộc Elsevier","scopus",[57],"SCOPUS","https:\u002F\u002Fwww.scopus.com\u002Fsourceid\u002F23154","1999-2025",[61],"d44e3b1d-4abe-47f2-b4aa-783c24a9f903","SCOPUS__Q3",{"id":64,"indexDatabase":65,"url":77,"indexYears":20,"academicFieldIds":78,"indexDatabaseRanking":20},"d6779a06-bf1b-45b0-979e-926c930c2606",{"id":66,"createTime":20,"updateTime":20,"relativeEntities":67,"label":68,"description":70,"key":73,"publicationTags":74,"standard":20},"88bab0f7-443b-476c-a72a-7fa5222da393",[],{"EN":69,"VI":69},"ISI\u002FESCI  - Emerging Sources Citation Index",{"EN":71,"VI":72},"ESCI database","Cơ sở dữ liệu ESCI","esci",[75,76],"ESCI","ISI","https:\u002F\u002Fmjl.clarivate.com\u002Fsearch-results?issn=1092-8464",[79],"22fd6c38-3ec0-41e0-8ae8-a4290171207e",{"impactFactor":21,"impactFactorByYear":81,"i10Index":93,"i10IndexLast5Year":94,"totalPublication":95,"totalPublicationByYear":96,"totalCitation":121,"totalCitationByYear":122,"totalCitationPerPublication":141,"totalCitationPerPublicationByYear":142,"hindexLast5Year":166,"hindex":166},{"2012":82,"2013":83,"2014":83,"2015":84,"2016":85,"2017":86,"2018":87,"2019":88,"2020":89,"2021":90,"2022":91,"2023":92},0.23,0.33,0.32,0.28,0.41,0.51,0.36,0.53,0.62,0.19,0.18,82,11,1175,{"1999":97,"2000":98,"2001":99,"2002":100,"2003":101,"2004":102,"2005":103,"2006":104,"2007":105,"2008":106,"2009":107,"2010":108,"2011":109,"2012":109,"2013":108,"2014":110,"2015":111,"2016":112,"2017":113,"2018":114,"2019":115,"2020":116,"2021":117,"2022":118,"2023":119,"2024":120},33,39,36,30,40,34,35,45,29,47,31,42,46,57,59,52,83,92,71,75,51,6,49,4,2296,{"1999":123,"2000":109,"2001":124,"2002":125,"2003":126,"2004":127,"2005":112,"2006":128,"2007":129,"2008":130,"2009":113,"2010":131,"2011":132,"2012":133,"2013":93,"2014":134,"2015":135,"2016":136,"2017":137,"2018":113,"2019":138,"2020":97,"2021":139,"2023":140},13,32,160,27,70,94,72,109,87,127,119,125,124,86,352,277,41,2,1.95,{"1999":143,"2000":144,"2001":145,"2002":146,"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2010":154,"2011":155,"2012":156,"2013":141,"2014":157,"2015":158,"2016":159,"2017":160,"2018":161,"2019":162,"2020":163,"2021":164,"2023":165},0.39,1.18,0.89,5.33,0.68,2.06,1.49,2.09,2.48,2.32,2.68,2.07,2.76,2.59,2.19,2.1,1.65,4.24,0.9,3.9,0.44,0.8,0.04,21,{"meta":168,"data":170},{"total":169},"1034",[171,693,784,872,984,1313,1429,1530,1616,1731],{"id":172,"createTime":173,"updateTime":174,"relativeEntities":175,"slug":176,"properties":177,"entityType":190,"verifyStatus":191,"verifyTime":192,"verifyNote":193,"languages":194,"translateLanguages":20,"viewCount":21,"primaryUrl":196,"fullTextUrl":20,"authors":197,"publicationType":248,"publisherRelationship":249,"citationCount":292,"citationInfo":293,"publishDate":296,"publishYear":294,"citationAnalyzeStatus":297,"lastCitationAnalyze":298,"indexDatabases":299,"openAccess":20,"references":300,"isForceReanalyzing":692},"7604dfd0-bacc-4f2d-8172-cc22a9e039fc","2024-04-15T01:48:11.328+00:00","2026-08-16T06:14:13.995+00:00",[],"Heart-Failure-in-Adults-who-had-the-Fontan-Procedure-Natural-History-Evaluation-and-Management",{"openalex":178,"mag":180,"title":182,"gsPaper":184,"pm":186,"doi":188},{"VOID":179},"W2078346313",{"VOID":181},"2078346313",{"EN":183},"Heart Failure in Adults who had the Fontan Procedure: Natural History, Evaluation, and Management",{"VOID":185},"[]",{"VOID":187},"23913280",{"VOID":189},"10.1007\u002Fs11936-013-0257-2","PUBLICATION","VERIFIED","2024-09-04T20:16:03.833+00:00","Auto Verify",[195],"EN","http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11936-013-0257-2",[198,217,233],{"id":199,"sortIndex":21,"researcher":20,"roles":200,"affiliations":201,"properties":210,"displayName":214,"givenName":20,"familyName":20},"80c81eca-caef-4804-9f8c-ea82cfe3fc23",[],[202],{"id":203,"sortIndex":21,"affiliation":204,"properties":20},"c2e3fa6a-0f64-4b72-85af-3a103346eee6",{"id":203,"createTime":20,"updateTime":20,"relativeEntities":205,"slug":20,"properties":206,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":209,"statistic":20},[],{"title":207},{"EN":208},"Saint Louis, USA",[],{"orcid":211,"title":213,"openalex":215},{"VOID":212},"https:\u002F\u002Forcid.org\u002F0000-0002-9975-5301",{"EN":214},"Ari Cedars",{"VOID":216},"A5050585132",{"id":218,"sortIndex":219,"researcher":20,"roles":220,"affiliations":221,"properties":228,"displayName":230,"givenName":20,"familyName":20},"628aa956-c758-41fe-b5a6-9514958fef4d",1,[],[222],{"id":203,"sortIndex":21,"affiliation":223,"properties":20},{"id":203,"createTime":20,"updateTime":20,"relativeEntities":224,"slug":20,"properties":225,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":227,"statistic":20},[],{"title":226},{"EN":208},[],{"title":229,"openalex":231},{"EN":230},"Susan Joseph",{"VOID":232},"A5084298779",{"id":234,"sortIndex":140,"researcher":20,"roles":235,"affiliations":236,"properties":243,"displayName":245,"givenName":20,"familyName":20},"4a48faba-39de-4a67-b0c5-5809571484e5",[],[237],{"id":203,"sortIndex":21,"affiliation":238,"properties":20},{"id":203,"createTime":20,"updateTime":20,"relativeEntities":239,"slug":20,"properties":240,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":242,"statistic":20},[],{"title":241},{"EN":208},[],{"title":244,"openalex":246},{"EN":245},"Philip A. Ludbrook",{"VOID":247},"A5076014535","ARTICLE",{"url":20,"publisher":250,"properties":20},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":251,"slug":10,"properties":252,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":256,"manageAffiliations":261,"indexDatabases":272,"url":20,"thumbnailPath":20,"statistic":287,"gsStatistic":20,"type":20,"analyzePriority":20},[],{"issn":253,"title":254,"eissn":255},{"VOID":13},{"EN":15},{"VOID":17},[257],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":258,"label":259,"description":260,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},[262,267],{"id":31,"createTime":20,"updateTime":20,"relativeEntities":263,"slug":20,"properties":264,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":266,"statistic":20},[],{"title":265},{"EN":35},[37],{"id":39,"createTime":20,"updateTime":20,"relativeEntities":268,"slug":20,"properties":269,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":271,"statistic":20},[],{"title":270},{"EN":43},[],[273,280],{"id":47,"indexDatabase":274,"url":58,"indexYears":59,"academicFieldIds":279,"indexDatabaseRanking":62},{"id":49,"createTime":20,"updateTime":20,"relativeEntities":275,"label":276,"description":277,"key":55,"publicationTags":278,"standard":20},[],{"EN":52,"VI":52},{"EN":52,"VI":54},[57],[61],{"id":64,"indexDatabase":281,"url":77,"indexYears":20,"academicFieldIds":286,"indexDatabaseRanking":20},{"id":66,"createTime":20,"updateTime":20,"relativeEntities":282,"label":283,"description":284,"key":73,"publicationTags":285,"standard":20},[],{"EN":69,"VI":69},{"EN":71,"VI":72},[75,76],[79],{"impactFactor":21,"impactFactorByYear":288,"i10Index":93,"i10IndexLast5Year":94,"totalPublication":95,"totalPublicationByYear":289,"totalCitation":121,"totalCitationByYear":290,"totalCitationPerPublication":141,"totalCitationPerPublicationByYear":291,"hindexLast5Year":166,"hindex":166},{"2012":82,"2013":83,"2014":83,"2015":84,"2016":85,"2017":86,"2018":87,"2019":88,"2020":89,"2021":90,"2022":91,"2023":92},{"1999":97,"2000":98,"2001":99,"2002":100,"2003":101,"2004":102,"2005":103,"2006":104,"2007":105,"2008":106,"2009":107,"2010":108,"2011":109,"2012":109,"2013":108,"2014":110,"2015":111,"2016":112,"2017":113,"2018":114,"2019":115,"2020":116,"2021":117,"2022":118,"2023":119,"2024":120},{"1999":123,"2000":109,"2001":124,"2002":125,"2003":126,"2004":127,"2005":112,"2006":128,"2007":129,"2008":130,"2009":113,"2010":131,"2011":132,"2012":133,"2013":93,"2014":134,"2015":135,"2016":136,"2017":137,"2018":113,"2019":138,"2020":97,"2021":139,"2023":140},{"1999":143,"2000":144,"2001":145,"2002":146,"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2010":154,"2011":155,"2012":156,"2013":141,"2014":157,"2015":158,"2016":159,"2017":160,"2018":161,"2019":162,"2020":163,"2021":164,"2023":165},7,{"total":292,"publishYear":294,"statisticByYear":295},2013,{"2016":140,"2017":140,"2018":219,"2021":219},"2013-10-01","ERROR_IN_GET_PLATFORM_ID","2026-08-16T06:14:13.994+00:00",[62,75],[301,305,308,312,316,320,324,328,332,336,340,344,348,352,356,360,364,368,372,376,380,384,388,392,396,400,404,407,411,415,418,422,426,430,434,438,442,446,449,453,457,461,465,469,473,477,481,485,489,493,497,501,505,509,513,517,521,525,529,533,537,541,545,549,553,557,561,565,569,573,577,581,584,588,592,596,600,604,608,612,616,620,624,628,632,636,640,644,648,652,656,660,664,668,672,676,680,684,688],{"id":20,"text":302,"url":20,"identifiers":303},"Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax. 1971;26:240–8.",{"doi":304},"10.1136\u002Fthx.26.3.240",{"id":20,"text":306,"url":20,"identifiers":307},"Puga FJ, Chiavarelli M, Hagler DJ. Modifications of the Fontan operation applicable to patients with left atrioventricular valve atresia or single atrioventricular valve. Circulation. 1987;76:11153–60.",{},{"id":20,"text":309,"url":20,"identifiers":310},"Jonas RA, Castaneda AR. Modified Fontan procedure: atrial baffle and systemic venous to pulmonary anastomotic techniques. J Card Surg. 1988;3:91–6.",{"doi":311},"10.1111\u002Fj.1540-8191.1988.tb00228.x",{"id":20,"text":313,"url":20,"identifiers":314},"Bjork VO, Olin CJ, Bjarke BB, Thoren CA. Right atrial-right ventricular anastomosis for correction of tricuspid atresia. J Thorac Cardiovasc Surg. 1979;77:452–8.",{"doi":315},"10.1016\u002FS0022-5223(19)40916-1",{"id":20,"text":317,"url":20,"identifiers":318},"Bull D, de Leval MR, Stark J, Taylor JF, Mccartney FJ. Use of a subpulmonary ventricular chamber in the Fontan circulation. J Thorac Cardiovasc Surg. 1983;85:21–31.",{"doi":319},"10.1016\u002FS0022-5223(19)38895-6",{"id":20,"text":321,"url":20,"identifiers":322},"de Leval MR, Kilner P, Gewillig M, Bull C. Total cavopulmonary connection: a logical alternative to atriopulmonary connection for complex Fontan operations. Experimental studies and early clinical experience. J Thorac Cardiovasc Surg. 1988;96:682–95.",{"doi":323},"10.1016\u002FS0022-5223(19)35174-8",{"id":20,"text":325,"url":20,"identifiers":326},"Marcelletti C, Corno A, Giannico S, Marino B. Inferior vena cava-pulmonary artery extracardiac conduit. A new form of right heart bypass. J Thorac Cardiovasc Surg. 1990;100:228–32.",{"doi":327},"10.1016\u002FS0022-5223(19)35562-X",{"id":20,"text":329,"url":20,"identifiers":330},"Van Haesdonck JM, Mertens L, Sizaire R, et al. Comparison by computerized numeric modeling of energy losses in different Fontan connections. Circulation. 1995;92:11322–6.",{"doi":331},"10.1161\u002F01.CIR.92.9.322",{"id":20,"text":333,"url":20,"identifiers":334},"Be’eri E, Maier SE, Landzberg MJ, Chung T, Geva T. In vivo evaluation of Fontan pathway flow dynamics by multidimensional phase-velocity magnetic resonance imaging. Circulation. 1998;98:2873–82.",{"doi":335},"10.1161\u002F01.CIR.98.25.2873",{"id":20,"text":337,"url":20,"identifiers":338},"Lardo AC, Webber SA, Friehs I, del Nido PJ, Cape EG. Fluid dynamic comparison of intra-atrial and extracardiac total cavopulmonary connections. J Thorac Cardiovasc Surg. 1999;117:697–704.",{"doi":339},"10.1016\u002FS0022-5223(99)70289-8",{"id":20,"text":341,"url":20,"identifiers":342},"Bove EL, de Leval MR, Migliavacca F, Guadagni G, Dubini G. Computational fluid dynamics in the evaluation of hemodynamic performance of cavopulmonary connections after the Norwood procedure for hypoplastic left heart syndrome. J Thorac Cardiovasc Surg. 2003;126:1040–7.",{"doi":343},"10.1016\u002FS0022-5223(03)00698-6",{"id":20,"text":345,"url":20,"identifiers":346},"d’ Udekem Y, Iyengar AJ, Cochrane AD, et al. The Fontan procedure: contemporary techniques have improved long-term outcomes. Circulation. 2007;116:I-157–64.",{"doi":347},"10.1161\u002FCIRCULATIONAHA.106.676445",{"id":20,"text":349,"url":20,"identifiers":350},"Khairy P, Fernandes SM, Mayer JE, et al. Long-term survival, modes of death, and predictors of mortality in patients with Fontan surgery. Circulation. 2008;117:85–92.",{"doi":351},"10.1161\u002FCIRCULATIONAHA.107.738559",{"id":20,"text":353,"url":20,"identifiers":354},"Diller GP, Giardini A, Dimopoulos K, et al. Predictors of morbidity and mortality in contemporary Fontan patients: results from a multicenter study including cardiopulmonary exercise testing in 321 patients. Eur Heart J. 2010;24:3073–83. Important contemporary review of long-term Fontan outcomes.",{"doi":355},"10.1093\u002Feurheartj\u002Fehq356",{"id":20,"text":357,"url":20,"identifiers":358},"Stamm C, Friehs I, Mayer Jr JE, et al. Long-term results of the lateral tunnel Fontan operation. J Thorac Cardiovasc Surg. 2001;121:28–41.",{"doi":359},"10.1067\u002Fmtc.2001.111422",{"id":20,"text":361,"url":20,"identifiers":362},"Nurnberg JH, Ovroutski S, Alexi-Meskishvili V, et al. New onset arrhythmias after the extracardiac conduit Fontan operation compared with the intra-atrial lateral tunnel procedure: early and midterm results. Ann Thorac Surg. 2004;78:1978–88.",{"doi":363},"10.1016\u002Fj.athoracsur.2004.02.107",{"id":20,"text":365,"url":20,"identifiers":366},"Stephenson EA, Lu M, Berul CI, et al. Arrhythmias in a contemporary Fontan cohort: prevalence and clinical associations in a multicenter cross-sectional study. J Am Coll Cardilol. 2010;11:890–6. Significant contemporary retrospective analysis of a large group of pediatric Fontan patients employing the Pediatric Heart Network database.",{"doi":367},"10.1016\u002Fj.jacc.2010.03.079",{"id":20,"text":369,"url":20,"identifiers":370},"Backer CL, Deal BJ, Mavroudis C, Franklin WH, Stewart RD. Conversion of the failed Fontan circulation. Cardiol Young. 2006;16 Suppl 1:85–91.",{"doi":371},"10.1017\u002FS1047951105002386",{"id":20,"text":373,"url":20,"identifiers":374},"Kao JM, Alejos JC, Grant PW, et al. Conversion of atriopulmonary to cavopulmonary anastomosis in management of late arrhythmias and atrial thrombosis. Ann Thorac Surg. 1994;58:1510–4.",{"doi":375},"10.1016\u002F0003-4975(94)91945-3",{"id":20,"text":377,"url":20,"identifiers":378},"Mavroudis C, Backer CL, Deal BJ, Johnsrude CL. Fontan conversion to cavopulmonary connection and arrhythmia circuit cryoablation. J Thorac Cardiovasc Surg. 1998;115:547–56.",{"doi":379},"10.1016\u002FS0022-5223(98)70316-2",{"id":20,"text":381,"url":20,"identifiers":382},"Giardini A, Pace Napoleone C, Specchia S, et al. Conversation of atriopulmonary Fontan to extracardiac total cavopulmonary connection improves cardiopulmonary function. Int J Cardiol. 2006;113:341–4.",{"doi":383},"10.1016\u002Fj.ijcard.2005.11.046",{"id":20,"text":385,"url":20,"identifiers":386},"Weinstein S, Cua C, Chan D, Davis JT. Outcome of symptomatic patients undergoing extracardiac Fontan conversion and cryoablation. J Thorac Cardiovasc Surg. 2003;126:529–36.",{"doi":387},"10.1016\u002FS0022-5223(03)00212-5",{"id":20,"text":389,"url":20,"identifiers":390},"Mavroudis C, Deal BJ, Backer CL, et al. J. Maxwel Chamberlain Memorial Paper for congenital heart surgery. 111 Fontan conversation with arrhythmia surgery: surgical lessons and outcomes. Ann Thorac Surg. 2007;84:1457–65.",{"doi":391},"10.1016\u002Fj.athoracsur.2007.06.079",{"id":20,"text":393,"url":20,"identifiers":394},"Takahashi K, Fynn-Thompson F, Cecchin F, et al. Clinical outcomes of Fontan conversion surgery with and without associated arrhythmia intervention. Int J Cardiol. 2009;137:260–6.",{"doi":395},"10.1016\u002Fj.ijcard.2008.06.074",{"id":20,"text":397,"url":20,"identifiers":398},"Aboulhosn J, Williams R, Shivkumar K, et al. Arrhythmias recurrence in adult patients with single ventricle physiology following surgical Fontan conversion. Congenit Heart Dis. 2010;5:430–4.",{"doi":399},"10.1111\u002Fj.1747-0803.2010.00443.x",{"id":20,"text":401,"url":20,"identifiers":402},"Sridhar A, Giamberti A, Foresti S, et al. Fontan conversion with concomitant arrhythmia surgery for the failing atriopulmonary connections: mid-term results from a single center. Cardiol Young. 2011;21:665–9.",{"doi":403},"10.1017\u002FS1047951111000643",{"id":20,"text":405,"url":20,"identifiers":406},"Mascio CE, Pasquali SK, Jacobs JP, Jacobs ML, Austin EH. Outcomes in adult congenital heart surgery: analysis of the Society of Thoracic Surgeons Database. J Am Coll Cardiol. 2011;142:1090–7.",{},{"id":20,"text":408,"url":20,"identifiers":409},"Giannakoulas G, Dimopoulos K, Yuksel S, et al. Atrial tachyarrhythmias late after Fontan operation are related to increase in mortality and hospitalization. Int J Cardiol. 2012;157:221–6. Contemporary evaluation of the importance of supraventricular arrhythmias in Fontan patients.",{"doi":410},"10.1016\u002Fj.ijcard.2010.12.049",{"id":20,"text":412,"url":20,"identifiers":413},"van den Bosch AE, Roos-Hesselink JW, Van Domburg R, et al. Long-term outcome and quality of life in adult patients after the Fontan operation. Am J Cardiol. 2004;93:1141–5.",{"doi":414},"10.1016\u002Fj.amjcard.2004.01.041",{"id":20,"text":416,"url":20,"identifiers":417},"Deal B, Mavroudis C, Backer C. Arrhythmia management in the Fontan patient. J Thorac Cardiovasc Surg. 2007;28:448–56.",{},{"id":20,"text":419,"url":20,"identifiers":420},"Kogon B. Is the extracardiac conduit the preferred Fontan approach for patients with univentricular hearts? Circulation. 2012;126:2511–5.",{"doi":421},"10.1161\u002FCIRCULATIONAHA.111.076398",{"id":20,"text":423,"url":20,"identifiers":424},"Yap SC, Harris L, Silversides CK, Downar E, Chauhan VS. Outcome of intra-atrial re-entrant tachycardia catheter ablation in adults with congenital heart disease: negative impact of age and complex atrial surgery. J Am Coll Cardiol. 2010;56:1589–96.",{"doi":425},"10.1016\u002Fj.jacc.2010.04.061",{"id":20,"text":427,"url":20,"identifiers":428},"McFaul RC, Tajik AJ, Mair DD, Danielson GK, Seward JB. Development of pulmonary arteriovenous shunt after superior vena cava-right pulmonary artery (Glenn) anastomosis. Report of four cases. Circulation. 1977;55:212–6.",{"doi":429},"10.1161\u002F01.CIR.55.1.212",{"id":20,"text":431,"url":20,"identifiers":432},"Srivastava D, Preminger T, Lock JE, et al. Hepatic venous blood and the development of pulmonary arteriovenous malformations in congenital heart disease. Circulation. 1995;92:1217–22.",{"doi":433},"10.1161\u002F01.CIR.92.5.1217",{"id":20,"text":435,"url":20,"identifiers":436},"Lee J, Menkis AH, Rosenberg HC. Reversal of pulmonary arteriovenous malformation after diversion of anomalous hepatic drainage. Ann Thorac Surg. 1998;65:848–9.",{"doi":437},"10.1016\u002FS0003-4975(98)00011-3",{"id":20,"text":439,"url":20,"identifiers":440},"Chang RK, Alejos JC, Atkinson D, et al. Bubble contrast echocardiography in detecting pulmonary arteriovenous shunting in children with univentricular heart after cavopulmonary anastomosis. J Am Coll Cardiol. 1999;33:2052–8.",{"doi":441},"10.1016\u002FS0735-1097(99)00096-0",{"id":20,"text":443,"url":20,"identifiers":444},"Gomes A, Benson L, George B, Laks H. Management of pulmonary arteriovenous fistulas after superior vena cava-right pulmonary artery (Glenn) anastomosis. J Thorac Cardiovasc Surg. 1984;87:636–9.",{"doi":445},"10.1016\u002FS0022-5223(19)37371-4",{"id":20,"text":447,"url":20,"identifiers":448},"Garham K, Sondheimer H, Schaffer M. Resolution of cavopulmonary shunt-associated pulmonary arteriovenous malformation after heart transplantation. J Heart Lung Transplant. 1997;16:1271–4.",{},{"id":20,"text":450,"url":20,"identifiers":451},"McElhinney DB, Kreutzer J, Lang P, et al. Incorporation of the hepatic veins into the cavopulmonary circulation in patients with heterotaxy and pulmonary arteriovenous malformations after a Kawashima procedure. Ann Thorac Surg. 2005;80:1597–603.",{"doi":452},"10.1016\u002Fj.athoracsur.2005.05.101",{"id":20,"text":454,"url":20,"identifiers":455},"McElhinney DB, Marshall AC, Lang P, Lock JE, Mayer Jr JE. Creation of a brachial arteriovenous fistula for treatment of pulmonary arteriovenous malformations after cavopulmonary anastomosis. Ann Thorac Surg. 2005;80:1604–9.",{"doi":456},"10.1016\u002Fj.athoracsur.2005.05.100",{"id":20,"text":458,"url":20,"identifiers":459},"Hickey EJ, Alghamdi AA, Elmi M, et al. Systemic arteriovenous fistulae for end-stage cyanosis after cavopulmonary connection: a useful bridge to transplantation. J Thorac Cardiovasc Surg. 2010;139:128–34.",{"doi":460},"10.1016\u002Fj.jtcvs.2008.11.074",{"id":20,"text":462,"url":20,"identifiers":463},"Tweddell JS, Nersesian M, Mussatto KA, et al. Fontan in the modern era: factors impacting mortality and morbidity. Ann Thorac Surg. 2009;88:1291–9.",{"doi":464},"10.1016\u002Fj.athoracsur.2009.05.076",{"id":20,"text":466,"url":20,"identifiers":467},"Fontan F, Kirklin JW, Fernandez G, et al. Outcome after a “perfect” Fontan operation. Circulation. 1990;81:1520–36.",{"doi":468},"10.1161\u002F01.CIR.81.5.1520",{"id":20,"text":470,"url":20,"identifiers":471},"Kirklin JK, Brown RN, Bryant AS, et al. Is the “perfect Fontan” operation routinely achievable in the modern era? Cardiol Young. 2008;18:328–36.",{"doi":472},"10.1017\u002FS1047951108002278",{"id":20,"text":474,"url":20,"identifiers":475},"Kaulitz R, Luhmer I, Bergmann F, Rodeck B, Hausdorf G. Sequelae after modified Fontan operation: postoperative hemodynamic data and organ function. Heart. 1997;78:154–9.",{"doi":476},"10.1136\u002Fhrt.78.2.154",{"id":20,"text":478,"url":20,"identifiers":479},"Magosso E, Cavalcanti S, Ursino M. Theoretical analysis of rest and exercise hemodynamics in patients with total cavopulmonary connection. Am J Physiol Heart Circ Physiol. 2002;282:H1018–34.",{"doi":480},"10.1152\u002Fajpheart.00231.2001",{"id":20,"text":482,"url":20,"identifiers":483},"Sarkola T, Jaeggi E, Slorach C, et al. Assessment of vascular remodeling after the Fontan procedure using a novel very high resolution ultrasound method: arterial wall thinning and venous thickening in late follow-up. Heart Vessels. 2013;28:66–75.",{"doi":484},"10.1007\u002Fs00380-011-0217-2",{"id":20,"text":486,"url":20,"identifiers":487},"Mace L, Dervanian P, Bourriez A, et al. Changes in venous return parameters associated with univentricular Fontan circulations. Am J Physiol Heart Circ Physiol. 2000;279:H2335–43.",{"doi":488},"10.1152\u002Fajpheart.2000.279.5.H2335",{"id":20,"text":490,"url":20,"identifiers":491},"Szabo G, Buhmann V, Graf A, et al. Ventricular energetic after the Fontan operation: contractility-afterload mismatch. J Thorac Cardiovasc Surg. 2003;125:1061–9.",{"doi":492},"10.1067\u002Fmtc.2003.405",{"id":20,"text":494,"url":20,"identifiers":495},"Khambadkone S, Li J, de Leval MR, et al. Basal pulmonary vascular resistance and nitric oxide responsiveness late after Fontan-type operation. Circulation. 2003;107:3204–8.",{"doi":496},"10.1161\u002F01.CIR.0000074210.49434.40",{"id":20,"text":498,"url":20,"identifiers":499},"Nogaki M, Senzaki H, Masutani S, et al. Ventricular energetic in Fontan circulation: evaluation with a theoretical model. Pediatr Int. 2000;42:651–7.",{"doi":500},"10.1046\u002Fj.1442-200x.2000.01316.x",{"id":20,"text":502,"url":20,"identifiers":503},"Gewillig MH, Lundstrom UR, Bull C, Wyse RK, Deanfield JE. Exercise responses in patients with congenital heart disease after Fontan repair: patterns and determinants of performance. J Am Coll Cardiol. 1990;15:1424–32.",{"doi":504},"10.1016\u002FS0735-1097(10)80034-8",{"id":20,"text":506,"url":20,"identifiers":507},"Ohuchi H, Takasugi H, Ohashi H, et al. Abnormalities of neurohormonal and cardiac autonomic nervous activities relate poorly to functional status in Fontan patients. Circulation. 2004;110:2601–8.",{"doi":508},"10.1161\u002F01.CIR.0000145545.83564.51",{"id":20,"text":510,"url":20,"identifiers":511},"Ohuchi H, Negishi J, Ono S, et al. Hyponatremia and its association with the neurohormonal activity and adverse clinical events in children and young adult patients after the Fontan operation. Congenit Heart Dis. 2011;6:304–12. Good evaluation of the neurohumoral response to fluid overload in Fontan patients.",{"doi":512},"10.1111\u002Fj.1747-0803.2011.00503.x",{"id":20,"text":514,"url":20,"identifiers":515},"Shachar GB, Fuhrman BP, Wang Y, Lucas Jr RV, Lock JE. Rest and exercise hemodynamics after the Fontan procedure. Circulation. 1982;65:1043–8.",{"doi":516},"10.1161\u002F01.CIR.65.6.1043",{"id":20,"text":518,"url":20,"identifiers":519},"Driscoll DJ, Danielson GK, Puga FJ, et al. Exercise tolerance and cardiorespiratory response to exercise after the Fontan operation for tricuspid atresia or functional single ventricle. J Am Coll Cardiol. 1986;7:1087–94.",{"doi":520},"10.1016\u002FS0735-1097(86)80227-3",{"id":20,"text":522,"url":20,"identifiers":523},"Cortes RG, Satomi G, Yoshigi M, Momma K. Maximal hemodynamic response after the Fontan procedure. Doppler evaluation during the treadmill test. Pediatr Cardiol. 1994;15:170–7.",{"doi":524},"10.1007\u002FBF00800671",{"id":20,"text":526,"url":20,"identifiers":527},"Durongpisitkul K, Driscoll DJ, Mahoney DW, et al. Cardiorespiratory response to exercise after modified Fontan operation: determinants of performance. J Am Coll Cardiol. 1997;29:785–90.",{"doi":528},"10.1016\u002FS0735-1097(96)00568-2",{"id":20,"text":530,"url":20,"identifiers":531},"Matsushita T, Matsuda H, Ogawa M, et al. Assessment of the intrapulmonary ventilation-perfusion distribution after the Fontan procedure for complex cardiac anomalies: relation to pulmonary hemodynamics. J Am Coll Cardiol. 1990;15:842–8.",{"doi":532},"10.1016\u002F0735-1097(90)90284-V",{"id":20,"text":534,"url":20,"identifiers":535},"Nir A, Driscoll DJ, Mottram CD, et al. Cardiorespiratory response to exercise after the Fontan operation: a serial study. J Am Coll Cardiol. 1993;22:216–20.",{"doi":536},"10.1016\u002F0735-1097(93)90837-Q",{"id":20,"text":538,"url":20,"identifiers":539},"Stromvall-Larsson E, Eriksson BO. Haemodynamic adaptation during exercise in Fontan patients at a long-term follow-up. Scand Cardiovasc J. 2003;37:107–12.",{"doi":540},"10.1080\u002F4017430310001221",{"id":20,"text":542,"url":20,"identifiers":543},"Giardini A, Hager A, Pace Napoleone C, Picchio FM. Natural history of exercise capacity after the Fontan operation: a longitudinal study. Ann Thorac Surg. 2008;85:818–21.",{"doi":544},"10.1016\u002Fj.athoracsur.2007.11.009",{"id":20,"text":546,"url":20,"identifiers":547},"Jahangiri M, Dreutzer J, Zurakowski D, Bacha E, Jonas RA. Evaluation of hemostatic and coagulation factor abnormalities in patients undergoing the Fontan operation. J Thorac Cardiovasc Surg. 2000;120:778–82.",{"doi":548},"10.1067\u002Fmtc.2000.108903",{"id":20,"text":550,"url":20,"identifiers":551},"Odegard KC, McGowan Jr FX, Zurakowski D, et al. Procoagulant and anticoagulant factor abnormalities following the Fontan procedure: increased factor VIII may predispose to thrombosis. J Thorac Cardiovasc Surg. 2003;125:1260–7.",{"doi":552},"10.1016\u002FS0022-5223(02)73605-2",{"id":20,"text":554,"url":20,"identifiers":555},"Ascuitto RJ, Ross-Ascuitto NT. Systemic-to-pulmonary collaterals: a source of flow energy loss in Fontan physiology. Pediatr Cardiol. 2004;25:472–81.",{"doi":556},"10.1007\u002Fs00246-004-0580-1",{"id":20,"text":558,"url":20,"identifiers":559},"Weber HS. Incidence and predictors for the development of significant supradiphragmatic decompressing venous collateral channels following creation of Fontan physiology. Cardiol Young. 2001;11:289–94.",{"doi":560},"10.1017\u002FS1047951101000312",{"id":20,"text":562,"url":20,"identifiers":563},"Heinemann M, Breuer J, Steger V, et al. Incidence and impact of systemic venous collateral development after Glenn and Fontan procedures. Thorac Cardiovasc Surg. 2001;49:172–8.",{"doi":564},"10.1055\u002Fs-2001-14339",{"id":20,"text":566,"url":20,"identifiers":567},"Valente AM, Bhatt B, Cook S, et al. The CALF (Congenital Heart Disease in Adults Lower Extremity Systemic Venous Health in Fontan Patients) study. J Am Coll Cardiol. 2010;56:144–50.",{"doi":568},"10.1016\u002Fj.jacc.2010.02.048",{"id":20,"text":570,"url":20,"identifiers":571},"Bhatt AB, Landzberg MJ, Gerhard-Herman M, et al. Pathophysiology of chronic venous insufficiency in adults with a Fontan circulation (a pre-defined substudy of the CALF investigation). Int J Cardiol. 2013;165:41–5. Excellent review of venous physiology in Fontan patients.",{"doi":572},"10.1016\u002Fj.ijcard.2011.07.053",{"id":20,"text":574,"url":20,"identifiers":575},"Krishnan US, Taneja I, Gewitz M, Young R, Stewart J. Peripheral vascular adaptation and orthostatic tolerance in Fontan physiology. Circulation. 2009;120:1775–83.",{"doi":576},"10.1161\u002FCIRCULATIONAHA.109.854331",{"id":20,"text":578,"url":20,"identifiers":579},"Hjortdal VE, Emmertsen K, Stenbog E, et al. Effects of exercise and respiration on blood flow in total cavopulmonary connection. Circulation. 2003;108:1227–31.",{"doi":580},"10.1161\u002F01.CIR.0000087406.27922.6B",{"id":20,"text":582,"url":20,"identifiers":583},"Cordina RL, O’Meagher S, Karmali A, et al. Resistance training improves cardiac output, exercise capacity, and tolerance to positive airway pressure in Fontan physiology. Int J Cardiol. 2012;S0167–5273(12):01386–1. Important indication of a potential future direction for Fontan therapy.",{},{"id":20,"text":585,"url":20,"identifiers":586},"Ovaert C, Thijs D, Dewolf D, et al. The effect of bosentan in patients with a failing Fontan circulation. Cardiol Young. 2009;19:331–9.",{"doi":587},"10.1017\u002FS1047951109990023",{"id":20,"text":589,"url":20,"identifiers":590},"Bowater SE, Weaver RA, Thorne SA, Clift PF. The safety and effects of bosentan in patients with a Fontan circulation. Congenit Heart Dis. 2012;7:243–9.",{"doi":591},"10.1111\u002Fj.1747-0803.2012.00635.x",{"id":20,"text":593,"url":20,"identifiers":594},"Schuuring MJ, Vis JC, van Dijk AP, et al. Impact of bosentan on exercise capacity in adults after the Fontan procedure: a randomized controlled trial. Eur J Heart Fail. 2013;15:690–8.",{"doi":595},"10.1093\u002Feurjhf\u002Fhft017",{"id":20,"text":597,"url":20,"identifiers":598},"Goldberg JK, French B, McBride MG, et al. Impact of oral sildenafil on exercise performance in children and young adults after the Fontan operation: a randomized, double-blind, placebo-controlled, crossover trial. Circulation. 2011;123:1185–93. Excellent randomized controlled trial of Sildenafil in a young adult Fontan population.",{"doi":599},"10.1161\u002FCIRCULATIONAHA.110.981746",{"id":20,"text":601,"url":20,"identifiers":602},"Goldberg DJ, French B, Szwast AL, et al. Impact of sildenafil on echocardiographic indices of myocardial performance after the Fontan operation. Pediatr Cardiol. 2012;33:689–96.",{"doi":603},"10.1007\u002Fs00246-012-0196-9",{"id":20,"text":605,"url":20,"identifiers":606},"Shabanian R, Shahbaznejad L, Razaghian A, et al. Sildenafil and ventriculo-arterial coupling in Fontan-palliated patients: a noninvasive echocardiographic assessment. Pediatr Cardiol. 2013;34:129–34. Significant investigation into the physiology of pulmonary vasodilator therapy in Fontan patients.",{"doi":607},"10.1007\u002Fs00246-012-0400-y",{"id":20,"text":609,"url":20,"identifiers":610},"Jacobs ML, Pourmoghadam KK. Thromboembolism and the role of anticoagulation in the Fontan patient. Pediatr Cardiol. 2007;28:457–64.",{"doi":611},"10.1007\u002Fs00246-007-9006-1",{"id":20,"text":613,"url":20,"identifiers":614},"Marrone C, Galasso G, Piccolo R, et al. Antiplatelet vs anticoagulation therapy after extracardiac conduit Fontan: a systematic review and meta-analysis. Pediatr Cardiol. 2011;32:32–9.",{"doi":615},"10.1007\u002Fs00246-010-9808-4",{"id":20,"text":617,"url":20,"identifiers":618},"Monagle P, Cochrane A, Roberts R, et al. A multicenter, randomized trial comparing heparin\u002Fwarfarin and acetylsalicylic acid as primary thromboprophylaxis for 2 years after the Fontan procedure in children. J Am Coll Cardiol. 2011;58:645–51.",{"doi":619},"10.1016\u002Fj.jacc.2011.01.061",{"id":20,"text":621,"url":20,"identifiers":622},"Rychik J, Gui-Yang S. Relation of mesenteric vascular resistance after Fontan operation and protein-losing enteropathy. Am J Cardiol. 2002;90:672–4.",{"doi":623},"10.1016\u002FS0002-9149(02)02584-5",{"id":20,"text":625,"url":20,"identifiers":626},"Mori Y, Shoji M, Nakanishi T, Fujii T, Nakazawa M. Elevated vascular endothelial growth factor levels are associated with aortopulmonary collateral vessels in patients before and after the Fontan procedure. Am Heart J. 2007;153:987–94.",{"doi":627},"10.1016\u002Fj.ahj.2007.03.009",{"id":20,"text":629,"url":20,"identifiers":630},"Stern HJ. The argument for aggressive coiling of aortopulmonary collaterals in single ventricle patients. Catheter Cardiovasc Interv. 2009;74:897–900.",{"doi":631},"10.1002\u002Fccd.22156",{"id":20,"text":633,"url":20,"identifiers":634},"Senzaki H, Masutani S, Ishido H, et al. Cardiac rest and reserve function in patients with Fontan circulation. J Am Coll Cardiol. 2006;47:2528–35.",{"doi":635},"10.1016\u002Fj.jacc.2006.03.022",{"id":20,"text":637,"url":20,"identifiers":638},"Mondesert B, Marcotte F, Mongeon FP, et al. Fontan circulation: success or failure? Can J Cardiol. 2013;29:811–20.",{"doi":639},"10.1016\u002Fj.cjca.2012.12.009",{"id":20,"text":641,"url":20,"identifiers":642},"Piran S, Veldtman G, Siu S, Webb GD, Liu PP. Heart failure and ventricular dysfunction in patients with single or systemic right ventricles. Circulation. 2002;105:1189–94.",{"doi":643},"10.1161\u002Fhc1002.105182",{"id":20,"text":645,"url":20,"identifiers":646},"Rathod RH, Prakash A, Powell AJ, Geva T. Myocardial fibrosis identified by cardiac magnetic resonance late gadolinium enhancement is associated with adverse ventricular mechanics and ventricular tachycardia late after fontan operation. J Am Coll Cardiol. 2010;55:1721–8.",{"doi":647},"10.1016\u002Fj.jacc.2009.12.036",{"id":20,"text":649,"url":20,"identifiers":650},"Kouatli AA, Garcia JA, Zellers TM, Weinstein EM, Mahony L. Enalapril does not enhance exercise capacity in patients after fontan procedure. Circulation. 1997;96:1507–12.",{"doi":651},"10.1161\u002F01.CIR.96.5.1507",{"id":20,"text":653,"url":20,"identifiers":654},"Shaddy RE, Boucek MM, Hsu DT, et al. Pediatric Carvedilol Study G. Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA. 2007;298:1171–9.",{"doi":655},"10.1001\u002Fjama.298.10.1171",{"id":20,"text":657,"url":20,"identifiers":658},"Giardini A, Balducci A, Specchia S, et al. Effect of sildenafil on haemodynamic response to exercise and exercise capacity in fontan patients. Eur Heart J. 2008;29:1681–7.",{"doi":659},"10.1093\u002Feurheartj\u002Fehn215",{"id":20,"text":661,"url":20,"identifiers":662},"Riemer RK, Amir G, Reichenbach SH, Reinhartz O. Mechanical support of total cavopulmonary connection with an axial flow pump. J Thorac Cardiovasc Surg. 2005;130:351–4.",{"doi":663},"10.1016\u002Fj.jtcvs.2004.12.037",{"id":20,"text":665,"url":20,"identifiers":666},"Vanderpluym C, Urschel S, Buchholz H. Advanced therapies for congenital heart disease: ventricular assist devices and heart transplantation. Can J Cardiol. 2013;29:796–802.",{"doi":667},"10.1016\u002Fj.cjca.2013.02.008",{"id":20,"text":669,"url":20,"identifiers":670},"Russo P, Wheeler A, Russo J, Tobias JD. Use of a ventricular assist device as a bridge to transplantation in a patient with single ventricle physiology and total cavopulmonary anastomosis. Pediatr Anesth. 2008;18:320–4.",{"doi":671},"10.1111\u002Fj.1460-9592.2008.02435.x",{"id":20,"text":673,"url":20,"identifiers":674},"Bhama JK, Shulman J, Bermudez CA, et al. Heart transplantation for adults with congenital heart disease: results in the modern era. J Heart Lung Transplant. 2013;32:499–504.",{"doi":675},"10.1016\u002Fj.healun.2013.01.1047",{"id":20,"text":677,"url":20,"identifiers":678},"Lamour JM, Kanter KR, Naftel DC, et al. The effect of age, diagnosis, and previous surgery in children and adults undergoing heart transplantation for congenital heart disease. J Am Coll Cardiol. 2009;54:160–5.",{"doi":679},"10.1016\u002Fj.jacc.2009.04.020",{"id":20,"text":681,"url":20,"identifiers":682},"Lamour JM, Addonizio LJ, Galantowicz ME, et al. Outcome after orthotopic cardiac transplantation in adults with congenital heart disease. Circulation. 1999;100:II200–5.",{"doi":683},"10.1161\u002F01.CIR.100.suppl_2.II-200",{"id":20,"text":685,"url":20,"identifiers":686},"Patel ND, Weiss ES, Allen JG, et al. Heart transplantation for adults with congenital heart disease: analysis of the united network for organ sharing database. Ann Thorac Surg. 2009;88:814–21. discussion 821–812.",{"doi":687},"10.1016\u002Fj.athoracsur.2009.04.071",{"id":20,"text":689,"url":20,"identifiers":690},"Bernstein D, Naftel D, Chin C, et al. Outcome of listing for cardiac transplantation for failed fontan: a multi-institutional study. Circulation. 2006;114:273–80.",{"doi":691},"10.1161\u002FCIRCULATIONAHA.105.548016",false,{"id":694,"createTime":695,"updateTime":696,"relativeEntities":697,"slug":698,"properties":699,"entityType":190,"verifyStatus":191,"verifyTime":710,"verifyNote":193,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":711,"fullTextUrl":20,"authors":712,"publicationType":248,"publisherRelationship":729,"citationCount":21,"citationInfo":777,"publishDate":780,"publishYear":778,"citationAnalyzeStatus":781,"lastCitationAnalyze":782,"indexDatabases":783,"openAccess":20,"references":20,"isForceReanalyzing":692},"80372519-8435-4ddf-80bc-dd6457fab652","2024-02-09T13:38:55.917+00:00","2026-07-28T07:48:54.604+00:00",[],"Cardiomyopathy-in-children",{"abstract":700,"title":702,"gsPaper":704,"references":706,"doi":708},{"EN":701},"|\n                  \n                    \n                  \n                  \n                    \n                  \n                  \n                    \n                  \n                  \n                    \n                  \n                \n                     ",{"EN":703},"Cardiomyopathy in children",{"VOID":705},"[\"5090639560574525462\"]",{"VOID":707},"Bernstein D: Diseases of the myocardium. In Nelson Textbook of Pediatrics. Edited by Behrman RE, Kliegman RM, Jenson HB. Philadelphia: W B Saunders Co; 2000:1430–1436.\nLipshultz SE, Sleeper LA, Tomkin JA, et al.: The incidence of pediatric cardiomyopathy; the prospective pediatric cardiomyopathy registry. J Am Coll Cardiol 2001, 37:465A-466A.\nTowbin JA: Pediatric myocardial disease. Pediatr Clin N Am 1999, 46:289–312.\nSchwartz ML, Cox G, Lin AE, et al.: Clinical approach to genetic cardiomyopathy in children. Circulation 1996, 94:2021–2038. A comprehensive review of the diagnostic approach to pediatric cardiomyopathy of genetic causes.\nBonne G, Carrier L, Richard P, et al.: Familial hypertrophic cardiomyopathy: from mutations to functional defects. Circ Res 1998, 83:580–593.\nPacker M, Bristow MR, Cohn JN, et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996, 334:1349–1355. A report of carvedilol therapy in patients with heart failure with beneficial effect.\nAzeka E, Ramires JAF, Z-baid M, et al.: Delisting for heart transplantation to treatment of dilated cardiomyopathy after starting carvedilol in infants and children. J Am Coll Cardiol 2001, 37:462A.\nPacker M, Cohn JN: Consensus recommendations for the management of chronic heart failure. Part II. Management of heart failure. Am J Cardiol 1999, 83:9A-38A. An up-to-date and comprehensive review of heart failure management.\nKleinert S, Weintraub RG, Wilkinson JL, et al.: Myocarditis in children with dilated cardiomyopathy: incidence and outcome after dual therapy immunosuppression. J Heart Lung Transplant 1997, 16:1248–1254.\nCamargo PR, Snitcowsky R, daLuz PL, et al.: Favorable effects of immunosuppressive therapy in children with dilated cardiomyopathy and active myocarditis. Pediatr Cardiol 1995, 16:61–68.\nGoldstein DJ, Oz MC, Rose EA: Implantable left ventricular assist devices. N Engl J Med 1998, 339:1522–1533.\nTakeda Y, Yasuda S, Miyazaki S, et al.: High dose immunoglobulin G therapy for fulminant myocarditis. Jpn Cir J 1998, 62:871–872.\nIno T, Sherwood WG, Benson LN, et al.: Cardiac manifestations in disorders of fat and carnitine metabolism in infancy. J Am Coll Cardiol 1988, 11:1301–1308.\nPierpont MEM, Breningstall GN, Stanley CA, et al.: The role of energy metabolism defects in cardiomyopathy: from inborn errors to ischemia. Am Heart J 2000, 139:S96-S106.\nKakkis ED, Muenzer J, Tiller GE, et al.: Enzyme replacement therapy in mucopolysaccharidosis. N Engl J Med 2001, 344:182–188.\nMaron BJ, Isner JM, McKenna WJ: 26th Bethesda Conference: recommendations for determining eligibility for competition in athletes with cardiovascular abnormalities. Task force 3: hypertrophic cardiomyopathy, myocarditis and other myopericardial diseases and mitral valve prolapse. J Am Coll Cardiol 1994, 24:880–885. Detailed recommendations for sport activities in patients with myocardial diseases.\nOstman-SmithI, Wettrell G, Riesenfeld T: A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment. J Am Coll Cardiol 1999, 34:1813–1822. The beneficial effect of a high-dose beta-blocker in children with hypertrophic cardiomyopathy from three regional centers is presented.\nYetman AT, Hamilton RM, Benson LN, et al.: Long-term outcome and prognostic determinants in children with hypertrophic cardiomyopathy. J Am Coll Cardiol 1998, 32:1943–1950.\nBrunner-La Schonbeck MH, Rocca HP, Vogt PR, et al.: Long-term follow-up in hypertrophic obstructive cardiomyopathy after septal myomectomy. Ann Thorac Surg 1998, 65:1207–1214.\nKappenberger L, Linde C, Daubert C, et al.: Pacing in hypertrophic obstructive cardiomyopathy. A randomized crossover study. PIC study group. Eur Heart J 1997, 18:1249–1256.\nMaron BJ, Shen WK, Link MS, et al.: Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000, 342:365–373.\nNagueh SF, Lakkis NM, Middleton KJ, et al.: Changes in left ventricular diastolic function 6 months after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy. Circulation 1999, 99:344–347.\nCox GF, Souri M, Aoyama T, et al.: Reversal of severe hypertrophic cardiomyopathy and excellent neuropsychologic outcome in very-long-chain acylcoenzyme A dehydrogenese deficiency. J Pediat 1998, 133:247–253.\nPeters C, Balthazor M, Shapiro EG, et al.: Outcome of unrelated donor bone marrow transplantation in 40 children with Hurler syndrome. Blood 1996, 87:4894–4902.\nKushawaha SS, Fallon JI, Fuster V: Restrictive cardiomyopathy. N Engl J Med 1997, 336:267–276. A comprehensive review of RCM.\nDenfield SW, Rosenthal G, Gajarski RJ, et al.: Restrictive cardiomyopathies in childhood, etiologies and natural history. Texas Heart Inst J 1997, 24:38–44.\nRivens SM, Kearney DL, Smith EO, et al.: Sudden death and cardiovascular collapse in children with restrictive cardiomyopathy. Circulation 2000, 102:876–882.\nAmmash N, Seward J, Bailey K, et al.: Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation 2000, 101:1490–2496.\nRothenberg ME: Eosinophilia. N Engl J Med 1998, 338:1592–1600.\nCorrado D, Basso C, Thiene G, et al.: Spectrum of clinicopathologic manifestations of arrhythmogenic right ventricular dysplasia: a multicenter study. J Am Coll Cardiol 1997, 30:1512–1520. A review of a large number of patients with ARVD.",{"VOID":709},"10.1007\u002Fs11936-001-0030-9","2024-05-13T07:14:42.072+00:00","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11936-001-0030-9",[713],{"id":714,"sortIndex":21,"researcher":20,"roles":715,"affiliations":717,"properties":726,"displayName":728,"givenName":20,"familyName":20},"b8df9113-b316-4548-9ad1-52a33a2292f0",[716],"AUTHOR",[718],{"id":719,"sortIndex":21,"affiliation":720,"properties":20},"ee126cac-318d-4851-803b-e2301dbaa3e8",{"id":719,"createTime":20,"updateTime":20,"relativeEntities":721,"slug":20,"properties":722,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":725,"statistic":20},[],{"title":723},{"VI":724},"Division of Pediatric Cardiology, Saint Louis University School of Medicine, St. Louis, USA",[],{"title":727},{"VI":728},"Su-chiung Chen",{"url":711,"publisher":730,"properties":772},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":731,"slug":10,"properties":732,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":736,"manageAffiliations":741,"indexDatabases":752,"url":20,"thumbnailPath":20,"statistic":767,"gsStatistic":20,"type":20,"analyzePriority":20},[],{"issn":733,"title":734,"eissn":735},{"VOID":13},{"EN":15},{"VOID":17},[737],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":738,"label":739,"description":740,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},[742,747],{"id":31,"createTime":20,"updateTime":20,"relativeEntities":743,"slug":20,"properties":744,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":746,"statistic":20},[],{"title":745},{"EN":35},[37],{"id":39,"createTime":20,"updateTime":20,"relativeEntities":748,"slug":20,"properties":749,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":751,"statistic":20},[],{"title":750},{"EN":43},[],[753,760],{"id":47,"indexDatabase":754,"url":58,"indexYears":59,"academicFieldIds":759,"indexDatabaseRanking":62},{"id":49,"createTime":20,"updateTime":20,"relativeEntities":755,"label":756,"description":757,"key":55,"publicationTags":758,"standard":20},[],{"EN":52,"VI":52},{"EN":52,"VI":54},[57],[61],{"id":64,"indexDatabase":761,"url":77,"indexYears":20,"academicFieldIds":766,"indexDatabaseRanking":20},{"id":66,"createTime":20,"updateTime":20,"relativeEntities":762,"label":763,"description":764,"key":73,"publicationTags":765,"standard":20},[],{"EN":69,"VI":69},{"EN":71,"VI":72},[75,76],[79],{"impactFactor":21,"impactFactorByYear":768,"i10Index":93,"i10IndexLast5Year":94,"totalPublication":95,"totalPublicationByYear":769,"totalCitation":121,"totalCitationByYear":770,"totalCitationPerPublication":141,"totalCitationPerPublicationByYear":771,"hindexLast5Year":166,"hindex":166},{"2012":82,"2013":83,"2014":83,"2015":84,"2016":85,"2017":86,"2018":87,"2019":88,"2020":89,"2021":90,"2022":91,"2023":92},{"1999":97,"2000":98,"2001":99,"2002":100,"2003":101,"2004":102,"2005":103,"2006":104,"2007":105,"2008":106,"2009":107,"2010":108,"2011":109,"2012":109,"2013":108,"2014":110,"2015":111,"2016":112,"2017":113,"2018":114,"2019":115,"2020":116,"2021":117,"2022":118,"2023":119,"2024":120},{"1999":123,"2000":109,"2001":124,"2002":125,"2003":126,"2004":127,"2005":112,"2006":128,"2007":129,"2008":130,"2009":113,"2010":131,"2011":132,"2012":133,"2013":93,"2014":134,"2015":135,"2016":136,"2017":137,"2018":113,"2019":138,"2020":97,"2021":139,"2023":140},{"1999":143,"2000":144,"2001":145,"2002":146,"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2010":154,"2011":155,"2012":156,"2013":141,"2014":157,"2015":158,"2016":159,"2017":160,"2018":161,"2019":162,"2020":163,"2021":164,"2023":165},{"pages":773,"volume":775},{"VOID":774},"403-413",{"VOID":776},"3",{"total":21,"publishYear":778,"statisticByYear":779},2001,{},"2001-10-01","DONE_ANALYZE_CITATION","2026-07-28T07:48:54.603+00:00",[62,75],{"id":785,"createTime":786,"updateTime":787,"relativeEntities":788,"slug":789,"properties":790,"entityType":190,"verifyStatus":191,"verifyTime":801,"verifyNote":193,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":802,"fullTextUrl":20,"authors":803,"publicationType":248,"publisherRelationship":819,"citationCount":21,"citationInfo":867,"publishDate":870,"publishYear":868,"citationAnalyzeStatus":19,"lastCitationAnalyze":787,"indexDatabases":871,"openAccess":20,"references":20,"isForceReanalyzing":692},"109c6d3f-1220-4d96-80bb-60bd012024a8","2023-12-27T00:39:51.552+00:00","2026-07-23T13:35:31.563+00:00",[],"Acute-Pulmonary-Embolus-The-Next-Frontier-in-Venous-Thromboembolic-Interventions",{"abstract":791,"title":793,"gsPaper":795,"references":797,"doi":799},{"EN":792},"Submassive pulmonary embolism (PE) represents a patient population that is under-recognized and under-treated. Recent clinical trials demonstrated the hemodynamic benefit of IV thrombolytic therapy among these patients; however, it came at the cost of a significantly increased risk of major, particularly intracranial, hemorrhage. Catheter-based treatment modalities have garnered considerable clinical interest in recent years. In particular, ultrasound accelerated thrombolysis, a catheter-based technology that enhances the process of thrombolytic delivery into the thrombus, has emerged as a treatment modality with an increasing number of single-center studies, as well as randomized, controlled clinical trials. Results from these experiences are consistent in achieving outcomes of thrombus resolution and hemodynamic recovery with a low dose thrombolytic infusion protocol, but without the high risk of bleeding complications associated with IV thrombolysis. The clinical data will hopefully be impactful to the development of the next edition of the treatment guidelines, in support of overall recommendations for catheter-based interventions. When available and with appropriate expertise, this modality should be considered as the preferred treatment of both massive and submassive PE.",{"EN":794},"Acute Pulmonary Embolus: The Next Frontier in Venous Thromboembolic Interventions",{"VOID":796},"[\"4894837513950416900\"]",{"VOID":798},"Wood KE. Major Pulmonary Embolism: Review of a Pathophysiologic Approach to the Golden Hour of Hemodynamically Significant Pulmonary Embolism. Chest. 2002;121:877–905.\nGoldhaber SZ, Visani L, De Rosa M. Acute Pulmonary Embolism: Clinical Outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353:1386–9.\nJaff MR, McMurtry MS, Archer SL, et al. Management of Massive and Submassive Pulmonary Embolism, Iliofemoral Deep Vein Thrombosis, and Chronic Thromboembolic Pulmonary Hypertension: A Scientific Statement from the American Heart Association. Circulation. 2011;123:1788–830. This is the first set of treatment guidelines that have provided a definition for risk stratification of acute PE patients.\nPiazza G, Goldhaber SZ. Fibrinolysis for Acute Pulmonary Embolism. Vasc Med. 2010;15:419–28.\nKennedy RJ, Kenney HH, Dunfee BL. Thrombus Resolution and Hemodynamic Recovery Using Ultrasound-Accelerated Thrombolysis in Acute Pulmonary Embolism. J Vasc Interv Radiol. 2013;24:841–8.\nEngelhardt TC, Taylor AJ, Simprini LA, Kucher N. Catheter-Directed Ultrasound-Accelerated Thrombolysis for the Treatment of Acute Pulmonary Embolism. Thromb Res 2011.\nQuiroz R, Kucher N, Schoepf UJ, et al. Right Ventricular Enlargement on Chest Computed Tomography: Prognostic Role in Acute Pulmonary Embolism. Circulation. 2004;109:2401–4.\nSchoepf UJ, Kucher N, Kipfmueller F, Quiroz R, Costello P, Goldhaber SZ. Right Ventricular Enlargement on Chest Computed Tomography: A Predictor of Early Death in Acute Pulmonary Embolism. Circulation. 2004;110:3276–80.\nFremont B, Pacouret G, Jacobi D, Puglisi R, Charbonnier B, de Labriolle A. Prognostic Value of Echocardiographic Right\u002FLeft Ventricular end-Diastolic Diameter Ratio in Patients With Acute Pulmonary Embolism: Results from a Monocenter Registry of 1,416 Patients. Chest. 2008;133:358–62.\nvan der Meer RW, Pattynama PM, van Strijen MJ, et al. Right Ventricular Dysfunction and Pulmonary Obstruction Index at Helical CT: Prediction of Clinical Outcome During 3-Month Follow-up in Patients With Acute Pulmonary Embolism. Radiology. 2005;235:798–803.\nGrifoni S, Vanni S, Magazzini S, et al. Association of Persistent Right Ventricular Dysfunction at Hospital Discharge After Acute Pulmonary Embolism With Recurrent Thromboembolic Events. Arch Intern Med. 2006;166:2151–6.\nTebbe U, Graf A, Kamke W, et al. Hemodynamic Effects of Double Bolus Reteplase Versus Alteplase Infusion in Massive Pulmonary Embolism. Am Heart J. 1999;138:39–44.\nKonstantinides S, Tiede N, Geibel A, Olschewski M, Just H, Kasper W. Comparison of Alteplase Versus Heparin for Resolution of Major Pulmonary Embolism. Am J Cardiol. 1998;82:966–70.\nBecattini C, Agnelli G, Salvi A, et al. Bolus Tenecteplase for Right Ventricle Dysfunction in Hemodynamically Stable Patients With Pulmonary Embolism. Thromb Res. 2010;125:e82–6.\nKearon C, Akl EA, Comerota AJ, et al. Antithrombotic Therapy for VTE Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e419S–94.\nFiumara K, Kucher N, Fanikos J, Goldhaber SZ. Predictors of Major Hemorrhage Following Fibrinolysis for Acute Pulmonary Embolism. Am J Cardiol. 2006;97:127–9.\nTorbicki A, Perrier A, Konstantinides S, et al. Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism: The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008;29:2276–315.\nKucher N, Rossi E, De Rosa M, Goldhaber SZ. Massive Pulmonary Embolism. Circulation. 2006;113:577–82.\nSharifi M, Bay C, Skrocki L, Rahimi F, Mehdipour M. Moderate Pulmonary Embolism Treated With Thrombolysis (from the \"MOPETT\" Trial). Am J Cardiol. 2013;111:273–7.\nKline JA, Nordenholz KE, Courtney DM, et al. Treatment of Submassive Pulmonary Embolism With Tenecteplase or Placebo: Cardiopulmonary Outcomes at Three Months TOPCOAT): Multicenter Double-Blind, Placebo-Controlled Randomized Trial. J Thromb Haemost 2014.\nKonstantinides S, Lankeit M. Pulmonary Embolism Hotline 2012. Recent and Expected Trials. Hamostaseologie. 2013;33:43–50.\nThe PEITHO Investigators. Pulmonary Embolism Thrombolysis Study: An Investigator-Initiated, Investigator-Sponsored Trial. 62nd Annual Meeting of the American College of Cardiology; San Francisco 2013. The PEITHO study is the largest prospective, randomized, controlled clinical trial to-date that evaluated IV thrombolysis against placebo for the treatment of submassive PE patients.\nKuo WT, Gould MK, Louie JD, Rosenberg JK, Sze DY, Hofmann LV. Catheter-Directed Therapy for the Treatment of Massive Pulmonary Embolism: Systematic Review and Meta-Analysis of Modern Techniques. J Vasc Interv Radiol. 2009;20:1431–40.\nFrancis CW, Blinc A, Lee S, Cox C. Ultrasound Accelerates Transport of Recombinant Tissue Plasminogen Activator into Clots. Ultrasound Med Biol. 1995;21:419–24.\nBraaten JV, Goss RA, Francis CW. Ultrasound Reversibly Disaggregates Fibrin Fibers. Thromb Haemost. 1997;78:1063–8.\nKucher N, Boekstegers P, Muller OJ, et al. Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism. Circulation. 2014;129:479–86. The ULTIMA is the first prospective, randomized, controlled, clinical trial that evaluated an advanced catheter-based treatment modality against standard-of-care therapy for acute PE patients.",{"VOID":800},"10.1007\u002Fs11936-014-0336-z","2024-05-13T15:32:03.988+00:00","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11936-014-0336-z",[804],{"id":805,"sortIndex":21,"researcher":20,"roles":806,"affiliations":807,"properties":816,"displayName":818,"givenName":20,"familyName":20},"2ed36a8e-05bb-42da-8210-d797816b5b66",[716],[808],{"id":809,"sortIndex":21,"affiliation":810,"properties":20},"83246d48-61bd-4eca-bdbb-a145541c25eb",{"id":809,"createTime":20,"updateTime":20,"relativeEntities":811,"slug":20,"properties":812,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":815,"statistic":20},[],{"title":813},{"VI":814},"Cardiovascular and Thoracic Surgery, Louisiana Heart, Lung and Vascular Institute, Metairie, USA",[],{"title":817},{"VI":818},"Tod C. Engelhardt",{"url":802,"publisher":820,"properties":862},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":821,"slug":10,"properties":822,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":826,"manageAffiliations":831,"indexDatabases":842,"url":20,"thumbnailPath":20,"statistic":857,"gsStatistic":20,"type":20,"analyzePriority":20},[],{"issn":823,"title":824,"eissn":825},{"VOID":13},{"EN":15},{"VOID":17},[827],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":828,"label":829,"description":830,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},[832,837],{"id":31,"createTime":20,"updateTime":20,"relativeEntities":833,"slug":20,"properties":834,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":836,"statistic":20},[],{"title":835},{"EN":35},[37],{"id":39,"createTime":20,"updateTime":20,"relativeEntities":838,"slug":20,"properties":839,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":841,"statistic":20},[],{"title":840},{"EN":43},[],[843,850],{"id":47,"indexDatabase":844,"url":58,"indexYears":59,"academicFieldIds":849,"indexDatabaseRanking":62},{"id":49,"createTime":20,"updateTime":20,"relativeEntities":845,"label":846,"description":847,"key":55,"publicationTags":848,"standard":20},[],{"EN":52,"VI":52},{"EN":52,"VI":54},[57],[61],{"id":64,"indexDatabase":851,"url":77,"indexYears":20,"academicFieldIds":856,"indexDatabaseRanking":20},{"id":66,"createTime":20,"updateTime":20,"relativeEntities":852,"label":853,"description":854,"key":73,"publicationTags":855,"standard":20},[],{"EN":69,"VI":69},{"EN":71,"VI":72},[75,76],[79],{"impactFactor":21,"impactFactorByYear":858,"i10Index":93,"i10IndexLast5Year":94,"totalPublication":95,"totalPublicationByYear":859,"totalCitation":121,"totalCitationByYear":860,"totalCitationPerPublication":141,"totalCitationPerPublicationByYear":861,"hindexLast5Year":166,"hindex":166},{"2012":82,"2013":83,"2014":83,"2015":84,"2016":85,"2017":86,"2018":87,"2019":88,"2020":89,"2021":90,"2022":91,"2023":92},{"1999":97,"2000":98,"2001":99,"2002":100,"2003":101,"2004":102,"2005":103,"2006":104,"2007":105,"2008":106,"2009":107,"2010":108,"2011":109,"2012":109,"2013":108,"2014":110,"2015":111,"2016":112,"2017":113,"2018":114,"2019":115,"2020":116,"2021":117,"2022":118,"2023":119,"2024":120},{"1999":123,"2000":109,"2001":124,"2002":125,"2003":126,"2004":127,"2005":112,"2006":128,"2007":129,"2008":130,"2009":113,"2010":131,"2011":132,"2012":133,"2013":93,"2014":134,"2015":135,"2016":136,"2017":137,"2018":113,"2019":138,"2020":97,"2021":139,"2023":140},{"1999":143,"2000":144,"2001":145,"2002":146,"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2010":154,"2011":155,"2012":156,"2013":141,"2014":157,"2015":158,"2016":159,"2017":160,"2018":161,"2019":162,"2020":163,"2021":164,"2023":165},{"pages":863,"volume":865},{"VOID":864},"1-8",{"VOID":866},"16",{"total":21,"publishYear":868,"statisticByYear":869},2014,{},"2014-07-30",[62,75],{"id":873,"createTime":874,"updateTime":875,"relativeEntities":876,"slug":877,"properties":878,"entityType":190,"verifyStatus":191,"verifyTime":888,"verifyNote":193,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":889,"fullTextUrl":20,"authors":890,"publicationType":248,"publisherRelationship":932,"citationCount":20,"citationInfo":20,"publishDate":980,"publishYear":981,"citationAnalyzeStatus":297,"lastCitationAnalyze":982,"indexDatabases":983,"openAccess":20,"references":20,"isForceReanalyzing":692},"fbc8c5a0-d044-4e0c-8163-64ec8a127568","2024-01-20T01:18:20.318+00:00","2026-07-22T01:35:33.744+00:00",[],"Management-of-Infrapopliteal-Peripheral-Arterial-Occlusive-Disease",{"abstract":879,"title":881,"gsPaper":883,"references":884,"doi":886},{"EN":880},"The management of infrapopliteal peripheral arterial occlusive disease (PAD) is challenging. For patients with asymptomatic disease or claudication, exercise and optimal medical management, including antiplatelet agents, blood pressure control, statin therapy and tight glucose control for patients with diabetes mellitus, are the mainstays of therapy. However, patients with isolated tibial artery occlusive disease often have diabetes mellitus or renal insufficiency and present with critical limb ischemia (CLI). CLI is advanced occlusive disease marked by the development of rest pain, ischemic ulceration, or gangrene and is associated with a high mortality rate. Limb salvage requires an intervention in cases of CLI, but careful operative planning is required as patients often have multilevel disease and limited options for revascularization. A surgical bypass with a vein graft remains the best treatment for infrapopliteal PAD, especially in patients with a life expectancy of over 2 years. Balloon angioplasty can play an important role in limb salvage, especially for patients lacking adequate vein for bypass, at high operative risk, or with a life expectancy of less than 2 years. However, a lack of rigorous trials has left unanswered questions as to the efficacy of infrapopliteal angioplasty with or without stents compared to bypass surgery. As such, endovascular therapy is currently not a proven treatment for intermittent claudication. Patients who are unable to undergo a revascularization procedure for infrapopliteal CLI have few options besides amputation or palliation. New therapies, such as drug-eluting stents, drug-coated balloons, and stem cell therapy are under development, but their efficacy and effectiveness remain unproven.",{"EN":882},"Management of Infrapopliteal Peripheral Arterial Occlusive Disease",{"VOID":185},{"VOID":885},"Norgren L, Hiatt W, Dormandy J, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). J Vasc Surg. 2007;45:S5–S67.\nGray BH, Grant AA, Kalbaugh CA, et al. The impact of isolated tibial disease on outcomes in the critical limb ischemic population. Ann Vasc Surg. 2010;24:349–59.\nHirsch AT, Haskal ZJ, Hertzer NR, et al. ACC\u002FAHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the american association for vascular surgery\u002Fsociety for vascular surgery, society for cardiovascular angiography and interventions, society for vascular medicine and biology, society of interventional radiology, and the ACC\u002FAHA task force on practice guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease): endorsed by the american association of cardiovascular and pulmonary rehabilitation; national heart, lung, and blood institute; society for vascular nursing; TransAtlantic inter-society consensus; and vascular disease foundation. Circulation. 2006;113:e463–654.\nRooke TW, Hirsch AT, Misra S, et al. 2011 ACCF\u002FAHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline): A Report of the American College of Cardiology Foundation\u002FAmerican Heart Association Task Force on Practice Guidelines. Circulation 2011, 124:2020–45.\nHamburg NM, Balady GJ. Exercise rehabilitation in peripheral artery disease: functional impact and mechanisms of benefits. Circulation. 2011;123:87–97.\nGrundy SM. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation. 2004;110:227–39.\nMomsen AH, Jensen MB, Norager CB, et al. Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies. Eur J Vasc Endovasc Surg. 2009;38:463–74.\nLane DA, Lip GY. Treatment of hypertension in peripheral arterial disease. Cochrane database of systematic reviews 2009:CD003075.\nDiehm C, Pittrow D, Lawall H. Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication. J Hypertens. 2011;29:1448–56.\nEspinola-Klein C, Weisser G, Jagodzinski A, et al. beta-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension. 2011;58:148–54.\nMohler ER. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation. 2003;108:1481–6.\nRidker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.\nGoodney PP, Beck AW, Nagle J, et al. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg. 2009;50:54–60.\nSadek M, Ellozy SH, Turnbull IC, et al. Improved outcomes are associated with multilevel endovascular intervention involving the tibial vessels compared with isolated tibial intervention. J Vasc Surg. 2009;49:638–44.\nFernandez N, McEnaney R, Marone LK, et al. Predictors of failure and success of tibial interventions for critical limb ischemia. J Vasc Surg 2010:1–9.\nGiles KA, Pomposelli FB, Hamdan AD, et al. Infrapopliteal angioplasty for critical limb ischemia: relation of TransAtlantic InterSociety consensus class to outcome in 176 limbs. J Vasc Surg. 2008;48:128–36.\nRomiti M, Albers M, Brochado-Neto FC, et al. Meta-analysis of infrapopliteal angioplasty for chronic critical limb ischemia. J Vasc Surg. 2008;47:975–81.e1.\nConrad MF, Kang J, Cambria RP, et al. Infrapopliteal balloon angioplasty for the treatment of chronic occlusive disease. J Vasc Surg. 2009;50:799–805.e4.\nDonas KP, Torsello G, Schwindt A, et al. Below knee bare nitinol stent placement in high-risk patients with critical limb ischemia is still durable after 24 months of follow-up. J Vasc Surg. 2010;52:356–61.\nSiablis D, Karnabatidis D, Katsanos K, et al. Infrapopliteal application of paclitaxel-eluting stents for critical limb ischemia: midterm angiographic and clinical results. J Vasc Interv Radiol. 2007;18:1351–61.\nSiablis D, Karnabatidis D, Katsanos K, et al. Infrapopliteal application of sirolimus-eluting versus bare metal stents for critical limb ischemia: analysis of long-term angiographic and clinical outcome. J Vasc Interv Radiol. 2009;20:1141–50.\nRandon C, Jacobs B, De Ryck F, Vermassen F. Angioplasty or primary stenting for infrapopliteal lesions: results of a prospective randomized trial. Cardiovasc Intervent Radiol. 2010;33:260–9.\nRastan A, Tepe G, Krankenberg H, et al. Sirolimus-eluting stents vs. bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. Eur Heart J. 2011;32:2274–81.\nStoner MC, deFreitas DJ, Phade SV, et al. Mid-term results with laser atherectomy in the treatment of infrainguinal occlusive disease. J Vasc Surg. 2007;46:289–95.\nZeller T, Sixt S, Schwarzwälder U, et al. Two-year results after directional atherectomy of infrapopliteal arteries with the SilverHawk device. J Endovasc Ther. 2007;14:232–40.\nBosiers M, Deloose K, Vermassen F, et al. The use of the cryoplasty technique in the treatment of infrapopliteal lesions for critical limb ischemia patients in a routine hospital setting: one-year outcome of the cryoplasty CLIMB registry. J Cardiovasc Surg (Torino). 2010;51:193–202.\nDas TS, McNamara T, Gray B, et al. Primary cryoplasty therapy provides durable support for limb salvage in critical limb ischemia patients with infrapopliteal lesions: 12-month follow-up results from the BTK Chill Trial. J Endovasc Ther. 2009;16:II19–30.\nSchmidt A, Piorkowski M, Werner M, et al. First experience with drug-eluting balloons in infrapopliteal arteries restenosis rate and clinical outcome. J Am Coll Cardiol. 2011;58:1105–9.\nYeh K-H, Tsai Y-J, Huang H-L, et al. Dual vascular access for critical limb ischemia: immediate and follow-up results. Catheter Cardiovasc Interv. 2011;77:296–302.\nBradbury AW, Adam DJ, Bell J, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: an intention-to-treat analysis of amputation-free and overall survival in patients randomized to a bypass surgery-first or a balloon angioplasty-first revascularization strategy. J Vasc Surg. 2010;51:5S–17S.\nBradbury AW, Adam DJ, Bell J, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: Analysis of amputation free and overall survival by treatment received. J Vasc Surg 2010, 51:18S–31S.\nForbes JF, Adam DJ, Bell J, et al. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial: health-related quality of life outcomes, resource utilization, and cost-effectiveness analysis. J Vasc Surg. 2010;51:43S–51S.\nConte MS, Geraghty PJ, Bradbury AW, et al. Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg 2009, 50:1462–73.e3.\nSchanzer A, Hevelone N, Owens CD, et al. Technical factors affecting autogenous vein graft failure: observations from a large multicenter trial. J Vasc Surg. 2007;46:1180–90. discussion 90.\nReed AB, Conte MS, Belkin M, et al. Usefulness of autogenous bypass grafts originating distal to the groin. J Vasc Surg. 2002;35:48–54. discussion, -5.\nAlbers M, Battistella VM, Romiti M, et al. Meta-analysis of polytetrafluoroethylene bypass grafts to infrapopliteal arteries. J Vasc Surg. 2003;37:1263–9.\nRandon C, Jacobs B, De Ryck F, et al. Fifteen years of infrapopliteal arterial reconstructions with cryopreserved venous allografts for limb salvage. J Vasc Surg. 2010;51:869–77.\nSultan S, Hamada N, Soylu E, et al. Sequential compression biomechanical device in patients with critical limb ischemia and nonreconstructible peripheral vascular disease. J Vasc Surg. 2011;54:440–7.\nKavros SJ, Delis KT, Turner NS, et al. Improving limb salvage in critical ischemia with intermittent pneumatic compression: a controlled study with 18-month follow-up. J Vasc Surg. 2008;47:543–9.\nUbbink DT, Vermeulen H. Spinal cord stimulation for critical leg ischemia: a review of effectiveness and optimal patient selection. J Pain Symptom Manage. 2006;31:S30–5.\nKlomp HM, Steyerberg EW, van Urk H, Habbema JD. Spinal cord stimulation is not cost-effective for non-surgical management of critical limb ischaemia. Eur J Vasc Endovasc Surg. 2006;31:500–8.\nCoventry BJ, Walsh JA. Cutaneous innervation in man before and after lumbar sympathectomy: evidence for interruption of both sensory and vasomotor nerve fibres. ANZ J Surg. 2003;73:14–8.\nNemes R, Surlin V, Chiutu L, et al. Retroperitoneoscopic lumbar sympathectomy: prospective study upon a series of 50 consecutive patients. Surg Endosc. 2011;25:3066–70.\nInvestigators O, Bot AI, Bosiers M. AMS INSIGHT—absorbable metal stent implantation for treatment of below-the-knee critical limb ischemia: 6-month analysis. Cardiovasc Intervent Radiol. 2008;32:424–35.\nPowell RJ, Goodney P, Mendelsohn FO, et al. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial. J Vasc Surg. 2010;52:1525–30.\nRajagopalan S, Mohler 3rd ER, Lederman RJ, et al. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation. 2003;108:1933–8.\nKusumanto YH, van Weel V, Mulder NH, et al. Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gen Ther. 2006;17:683–91.\nAmann B, Luedemann C, Ratei R, Schmidt-Lucke JA. Autologous bone marrow cell transplantation increases leg perfusion and reduces amputations in patients with advanced critical limb ischemia due to peripheral artery disease. Cell Transplant. 2009;18:371–80.\nTateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet. 2002;360:427–35.\nPowell RJ, Comerota AJ, Berceli SA, et al. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia. J Vasc Surg. 2011;54:1032–41.\nClinicalTrials.gov. Available at: http:\u002F\u002Fclinicaltrials.gov\u002F. Accessed August 2011.\nMartens JM, Knippenberg B, Vos JA, et al. Update on PADI trial: percutaneous transluminal angioplasty and drug-eluting stents for infrapopliteal lesions in critical limb ischemia. J Vasc Surg. 2009;50:687–9.\nBosiers M, Deloose K, Callaert J, et al. Drug-eluting stents below the knee. J Cardiovasc Surg (Torino). 2011;52:231–4.\nZeller T, Schmitmeier S, Tepe G, Rastan A. Drug-coated balloons in the lower limb. J Cardiovasc Surg (Torino). 2011;52:235–43.",{"VOID":887},"10.1007\u002Fs11936-012-0164-y","2024-06-26T21:07:50.919+00:00","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11936-012-0164-y",[891,906,919],{"id":892,"sortIndex":21,"researcher":20,"roles":893,"affiliations":894,"properties":903,"displayName":905,"givenName":20,"familyName":20},"117f059b-44bb-41c1-96e1-5d5b7b722ad7",[716],[895],{"id":896,"sortIndex":21,"affiliation":897,"properties":20},"2f4d95e3-5b35-4f98-ae4b-14999c19ed9a",{"id":896,"createTime":20,"updateTime":20,"relativeEntities":898,"slug":20,"properties":899,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":902,"statistic":20},[],{"title":900},{"VI":901},"Department of Surgery, Division of Vascular Surgery, University of California San Francisco, San Francisco, USA",[],{"title":904},{"VI":905},"Warren J. Gasper",{"id":907,"sortIndex":219,"researcher":20,"roles":908,"affiliations":909,"properties":916,"displayName":918,"givenName":20,"familyName":20},"b89cb795-95c4-49f7-956b-66f4cce3afe7",[716],[910],{"id":896,"sortIndex":21,"affiliation":911,"properties":20},{"id":896,"createTime":20,"updateTime":20,"relativeEntities":912,"slug":20,"properties":913,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":915,"statistic":20},[],{"title":914},{"VI":901},[],{"title":917},{"VI":918},"Sara J. Runge",{"id":920,"sortIndex":140,"researcher":20,"roles":921,"affiliations":922,"properties":929,"displayName":931,"givenName":20,"familyName":20},"1bbca0a8-1b10-4a35-ae24-0ff8318639c1",[716],[923],{"id":896,"sortIndex":21,"affiliation":924,"properties":20},{"id":896,"createTime":20,"updateTime":20,"relativeEntities":925,"slug":20,"properties":926,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":928,"statistic":20},[],{"title":927},{"VI":901},[],{"title":930},{"VI":931},"Christopher D. Owens",{"url":889,"publisher":933,"properties":975},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":934,"slug":10,"properties":935,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":939,"manageAffiliations":944,"indexDatabases":955,"url":20,"thumbnailPath":20,"statistic":970,"gsStatistic":20,"type":20,"analyzePriority":20},[],{"issn":936,"title":937,"eissn":938},{"VOID":13},{"EN":15},{"VOID":17},[940],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":941,"label":942,"description":943,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},[945,950],{"id":31,"createTime":20,"updateTime":20,"relativeEntities":946,"slug":20,"properties":947,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":949,"statistic":20},[],{"title":948},{"EN":35},[37],{"id":39,"createTime":20,"updateTime":20,"relativeEntities":951,"slug":20,"properties":952,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":954,"statistic":20},[],{"title":953},{"EN":43},[],[956,963],{"id":47,"indexDatabase":957,"url":58,"indexYears":59,"academicFieldIds":962,"indexDatabaseRanking":62},{"id":49,"createTime":20,"updateTime":20,"relativeEntities":958,"label":959,"description":960,"key":55,"publicationTags":961,"standard":20},[],{"EN":52,"VI":52},{"EN":52,"VI":54},[57],[61],{"id":64,"indexDatabase":964,"url":77,"indexYears":20,"academicFieldIds":969,"indexDatabaseRanking":20},{"id":66,"createTime":20,"updateTime":20,"relativeEntities":965,"label":966,"description":967,"key":73,"publicationTags":968,"standard":20},[],{"EN":69,"VI":69},{"EN":71,"VI":72},[75,76],[79],{"impactFactor":21,"impactFactorByYear":971,"i10Index":93,"i10IndexLast5Year":94,"totalPublication":95,"totalPublicationByYear":972,"totalCitation":121,"totalCitationByYear":973,"totalCitationPerPublication":141,"totalCitationPerPublicationByYear":974,"hindexLast5Year":166,"hindex":166},{"2012":82,"2013":83,"2014":83,"2015":84,"2016":85,"2017":86,"2018":87,"2019":88,"2020":89,"2021":90,"2022":91,"2023":92},{"1999":97,"2000":98,"2001":99,"2002":100,"2003":101,"2004":102,"2005":103,"2006":104,"2007":105,"2008":106,"2009":107,"2010":108,"2011":109,"2012":109,"2013":108,"2014":110,"2015":111,"2016":112,"2017":113,"2018":114,"2019":115,"2020":116,"2021":117,"2022":118,"2023":119,"2024":120},{"1999":123,"2000":109,"2001":124,"2002":125,"2003":126,"2004":127,"2005":112,"2006":128,"2007":129,"2008":130,"2009":113,"2010":131,"2011":132,"2012":133,"2013":93,"2014":134,"2015":135,"2016":136,"2017":137,"2018":113,"2019":138,"2020":97,"2021":139,"2023":140},{"1999":143,"2000":144,"2001":145,"2002":146,"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2010":154,"2011":155,"2012":156,"2013":141,"2014":157,"2015":158,"2016":159,"2017":160,"2018":161,"2019":162,"2020":163,"2021":164,"2023":165},{"pages":976,"volume":978},{"VOID":977},"136-148",{"VOID":979},"14","2012-01-17",2012,"2026-07-22T01:35:33.743+00:00",[62,75],{"id":985,"createTime":986,"updateTime":987,"relativeEntities":988,"slug":989,"properties":990,"entityType":190,"verifyStatus":191,"verifyTime":1003,"verifyNote":193,"languages":1004,"translateLanguages":20,"viewCount":21,"primaryUrl":1005,"fullTextUrl":20,"authors":1006,"publicationType":248,"publisherRelationship":1024,"citationCount":21,"citationInfo":1067,"publishDate":1070,"publishYear":1068,"citationAnalyzeStatus":19,"lastCitationAnalyze":1071,"indexDatabases":1072,"openAccess":20,"references":1073,"isForceReanalyzing":692},"a3fe3ed0-67c7-4f91-8132-ea6a70e4d9d0","2024-04-16T00:44:01.426+00:00","2026-07-20T19:47:34.751+00:00",[],"Treatment-of-venous-thromboembolism-in-pregnancy",{"openalex":991,"mag":993,"title":995,"gsPaper":997,"pm":999,"doi":1001},{"VOID":992},"W2001112339",{"VOID":994},"2001112339",{"EN":996},"Treatment of venous thromboembolism in pregnancy",{"VOID":998},"[\"9137111941976031152\"]",{"VOID":1000},"15066244",{"VOID":1002},"10.1007\u002Fs11936-004-0043-2","2024-06-23T18:26:40.842+00:00",[195],"http:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11936-004-0043-2",[1007],{"id":1008,"sortIndex":21,"researcher":20,"roles":1009,"affiliations":1010,"properties":1019,"displayName":1021,"givenName":20,"familyName":20},"27175a4a-0dfd-4f5b-a08c-8bdd3911d2ca",[],[1011],{"id":1012,"sortIndex":21,"affiliation":1013,"properties":20},"decd9a84-72a4-424a-a8b1-99ab59cd0d84",{"id":1012,"createTime":20,"updateTime":20,"relativeEntities":1014,"slug":20,"properties":1015,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1018,"statistic":20},[],{"title":1016},{"EN":1017},"Department of Medicine, University of Toronto, Women’s College Ambulatory Care Centre, Sunnybrook and Women’s College Health Sciences Centre, 76 Grenville Street, M5S 1B2, Toronto, Ontario, Canada",[],{"title":1020,"openalex":1022},{"EN":1021},"Wee‐Shian Chan",{"VOID":1023},"A5091223835",{"url":20,"publisher":1025,"properties":20},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1026,"slug":10,"properties":1027,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":1031,"manageAffiliations":1036,"indexDatabases":1047,"url":20,"thumbnailPath":20,"statistic":1062,"gsStatistic":20,"type":20,"analyzePriority":20},[],{"issn":1028,"title":1029,"eissn":1030},{"VOID":13},{"EN":15},{"VOID":17},[1032],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":1033,"label":1034,"description":1035,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},[1037,1042],{"id":31,"createTime":20,"updateTime":20,"relativeEntities":1038,"slug":20,"properties":1039,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1041,"statistic":20},[],{"title":1040},{"EN":35},[37],{"id":39,"createTime":20,"updateTime":20,"relativeEntities":1043,"slug":20,"properties":1044,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1046,"statistic":20},[],{"title":1045},{"EN":43},[],[1048,1055],{"id":47,"indexDatabase":1049,"url":58,"indexYears":59,"academicFieldIds":1054,"indexDatabaseRanking":62},{"id":49,"createTime":20,"updateTime":20,"relativeEntities":1050,"label":1051,"description":1052,"key":55,"publicationTags":1053,"standard":20},[],{"EN":52,"VI":52},{"EN":52,"VI":54},[57],[61],{"id":64,"indexDatabase":1056,"url":77,"indexYears":20,"academicFieldIds":1061,"indexDatabaseRanking":20},{"id":66,"createTime":20,"updateTime":20,"relativeEntities":1057,"label":1058,"description":1059,"key":73,"publicationTags":1060,"standard":20},[],{"EN":69,"VI":69},{"EN":71,"VI":72},[75,76],[79],{"impactFactor":21,"impactFactorByYear":1063,"i10Index":93,"i10IndexLast5Year":94,"totalPublication":95,"totalPublicationByYear":1064,"totalCitation":121,"totalCitationByYear":1065,"totalCitationPerPublication":141,"totalCitationPerPublicationByYear":1066,"hindexLast5Year":166,"hindex":166},{"2012":82,"2013":83,"2014":83,"2015":84,"2016":85,"2017":86,"2018":87,"2019":88,"2020":89,"2021":90,"2022":91,"2023":92},{"1999":97,"2000":98,"2001":99,"2002":100,"2003":101,"2004":102,"2005":103,"2006":104,"2007":105,"2008":106,"2009":107,"2010":108,"2011":109,"2012":109,"2013":108,"2014":110,"2015":111,"2016":112,"2017":113,"2018":114,"2019":115,"2020":116,"2021":117,"2022":118,"2023":119,"2024":120},{"1999":123,"2000":109,"2001":124,"2002":125,"2003":126,"2004":127,"2005":112,"2006":128,"2007":129,"2008":130,"2009":113,"2010":131,"2011":132,"2012":133,"2013":93,"2014":134,"2015":135,"2016":136,"2017":137,"2018":113,"2019":138,"2020":97,"2021":139,"2023":140},{"1999":143,"2000":144,"2001":145,"2002":146,"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2010":154,"2011":155,"2012":156,"2013":141,"2014":157,"2015":158,"2016":159,"2017":160,"2018":161,"2019":162,"2020":163,"2021":164,"2023":165},{"total":21,"publishYear":1068,"statisticByYear":1069},2004,{},"2004-04-01","2026-07-20T19:47:34.750+00:00",[62,75],[1074,1078,1082,1085,1088,1091,1094,1098,1102,1106,1110,1114,1118,1121,1125,1129,1133,1137,1141,1145,1149,1153,1157,1161,1165,1169,1173,1177,1181,1185,1189,1193,1197,1201,1205,1209,1213,1217,1221,1225,1229,1233,1237,1241,1245,1249,1253,1257,1261,1264,1268,1272,1276,1280,1284,1287,1291,1294,1297,1301,1305,1309],{"id":20,"text":1075,"url":20,"identifiers":1076},"Hull RD, Hirsh J, Carter CJ, et al.: Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med 1983, 98:891–899.",{"doi":1077},"10.7326\u002F0003-4819-98-6-891",{"id":20,"text":1079,"url":20,"identifiers":1080},"Sachs BP, Brown DA, Driscoll ST, et al.: Maternal mortality in Massachusetts. Trends and prevention. N Engl J Med 1987, 316:607–672.",{"doi":1081},"10.1056\u002FNEJM198703123161105",{"id":20,"text":1083,"url":20,"identifiers":1084},"London HMSO: Report on Confidential Inquiries into Maternal Deaths for England and Wales 1979–1981. Norwich, UK: London HMSO; 1986. http:\u002F\u002F www.hmso.gov.uk.",{},{"id":20,"text":1086,"url":20,"identifiers":1087},"Kaunitiz AM, Hughes JM, Grimes DA, et al.: Causes of maternal mortality in the US. Obstet Gynecol 1985, 65:605–612.",{},{"id":20,"text":1089,"url":20,"identifiers":1090},"Rochat RW, Koorin LM, Atrash HK, Jewett JF: Maternal mortality in the United States: report from the Maternal Mortality Collaborative. Obstet Gynecol 1988, 72:91–97.",{},{"id":20,"text":1092,"url":20,"identifiers":1093},"Mclean R, Mattison ET, Cochrane NE: Maternal mortality study. I. Annual report. 1970–1976. NY State J Med 1979, 79:39–46.",{},{"id":20,"text":1095,"url":20,"identifiers":1096},"Anderson BS, Steffensen FH, Sorensen HT, et al.: The cumulative incidence of venous thromboembolism during pregnancy and puerperium: an 11 year Danish population based study of 63,300 pregnancies. Acta Obstet Gynecol Scand 1998, 77:110–113.",{"doi":1097},"10.1080\u002F00016349808565823",{"id":20,"text":1099,"url":20,"identifiers":1100},"Rutherford SF, Phelan JP: Thromboembolic disease in pregnancy. Clin Perinatol 1980, 13:719–739.",{"doi":1101},"10.1016\u002FS0095-5108(18)30795-4",{"id":20,"text":1103,"url":20,"identifiers":1104},"Nordstrom M, Lindblad B: A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992, 232:155–160.",{"doi":1105},"10.1111\u002Fj.1365-2796.1992.tb00565.x",{"id":20,"text":1107,"url":20,"identifiers":1108},"Heit JA, Silverstein MD, Mohr DN, et al.: The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001, 86:452–463.",{"doi":1109},"10.1055\u002Fs-0037-1616243",{"id":20,"text":1111,"url":20,"identifiers":1112},"Reid DE, Frigoletto FD, Tullis JL: Hypercoagulable states in pregnancy. Am J Obstet Gynecol 1971, 111:493–504.",{"doi":1113},"10.1016\u002F0002-9378(71)90465-0",{"id":20,"text":1115,"url":20,"identifiers":1116},"Stirling Y, Woolf L, North WR, et al.: Hemostasis in normal pregnancy. Thromb Haemost 1984, 52:176–182.",{"doi":1117},"10.1055\u002Fs-0038-1661167",{"id":20,"text":1119,"url":20,"identifiers":1120},"Bonnar J: Blood coagulation fibrinolysis in obstetrics. Clin Hematol 1973, 12:58–63.",{},{"id":20,"text":1122,"url":20,"identifiers":1123},"Bonnar J, McNicol GP, Douglas AS: The blood coagulation and fibrinolytic system in the newborn and mother at birth. J Obstet Gynaecol Br Commonw 1971, 78:355–360.",{"doi":1124},"10.1111\u002Fj.1471-0528.1971.tb00285.x",{"id":20,"text":1126,"url":20,"identifiers":1127},"Comp PC, Thurnau GR, Welsh J, Esmon CT: Functional and immunologic protein S levels are decreased during pregnancy. Blood 1986, 68:881–885.",{"doi":1128},"10.1182\u002Fblood.V68.4.881.881",{"id":20,"text":1130,"url":20,"identifiers":1131},"Cordts PR, Gawley T: Anatomic and physiologic changes in lower extremity venous hemodynamics associated with pregnanc. 1996, 24:763–767.",{"doi":1132},"10.1016\u002FS0741-5214(96)70010-1",{"id":20,"text":1134,"url":20,"identifiers":1135},"Palmgren J, Kirkinen P: Venous circulation in the maternal lower limb: a Doppler study with the Valsalva maneuver. Ultrasound Obstet Gynecol 1996, 8:93–97.",{"doi":1136},"10.1046\u002Fj.1469-0705.1996.08020093.x",{"id":20,"text":1138,"url":20,"identifiers":1139},"Macklon NC, Greer IA, Bowman AW: An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynecol 1997, 104:191–197.",{"doi":1140},"10.1111\u002Fj.1471-0528.1997.tb11043.x",{"id":20,"text":1142,"url":20,"identifiers":1143},"Villa Santa U: Thromboembolic disease in pregnancy. Am J Obstet Gynecol 1965, 93:142–146.",{"doi":1144},"10.1016\u002F0002-9378(65)90308-X",{"id":20,"text":1146,"url":20,"identifiers":1147},"Barnes RW, Wu KK, Hoak JC: Fallibility of clinical diagnosis of venous thrombosis. JAMA 1975, 234:605–607.",{"doi":1148},"10.1001\u002Fjama.1975.03260190033017",{"id":20,"text":1150,"url":20,"identifiers":1151},"Kearon C, Julian JA, Newman TE, Ginsberg JS: Noninvasive diagnosis of deep venous thrombosis: McMaster Diagnostic Imaging Practice Guidelines Initiative. Ann Intern Med 1998, 128:663–677.",{"doi":1152},"10.7326\u002F0003-4819-128-8-199804150-00011",{"id":20,"text":1154,"url":20,"identifiers":1155},"Hull RD, Raskob GE, Coates G, et al.: A new noninvasive management strategy for patients with suspected pulmonary embolism. Arch Intern Med 1989, 149:2549–2555.",{"doi":1156},"10.1001\u002Farchinte.1989.00390110105024",{"id":20,"text":1158,"url":20,"identifiers":1159},"Value of the ventilation\u002Fperfusion scan in acute pulmonary embolism: results of the Prospective investigation of Pulmonary Embolism Diagnosis (PIOPED). The PIOPED investigators [no authors listed]. JAMA 1990, 263:2753–2759.",{"doi":1160},"10.1001\u002Fjama.1990.03440200057023",{"id":20,"text":1162,"url":20,"identifiers":1163},"Chan WS, Ginsberg JS: Diagnosis of deep vein thrombosis and pulmonary embolism in pregnancy. Thromb Res 2002, 107:85–91. An updated approach to the objective diagnosis of both PE and DVT in pregnancy.",{"doi":1164},"10.1016\u002FS0049-3848(02)00105-6",{"id":20,"text":1166,"url":20,"identifiers":1167},"Chan WS, J Ray, Coady G, et al.: Clinical presentation of suspected pulmonary embolism during pregnancy, VQ lung scan: results, and subsequent maternal and pediatric outcomes. Arch Intern Med 2002, 162:1170–1175.",{"doi":1168},"10.1001\u002Farchinte.162.10.1170",{"id":20,"text":1170,"url":20,"identifiers":1171},"Ginsberg JS, I Greer, Hirsh J: Use of antithrombotic agents during pregnancy. Chest 2001, 119:122S-131S. Major consensus report by the American College of Chest Physicians on the indications and use of antithrombotic therapy for various conditions during pregnancy.",{"doi":1172},"10.1378\u002Fchest.119.1_suppl.122S",{"id":20,"text":1174,"url":20,"identifiers":1175},"Chan WS, Ginsberg JS: Anticoagulation of pregnant women with mechanical heart valves: a systemic review of the literature. Arch Intern Med 2000, 160:191–196.",{"doi":1176},"10.1001\u002Farchinte.160.2.191",{"id":20,"text":1178,"url":20,"identifiers":1179},"Chan WS, Chunilal SD, Ginsberg JS: Antithrombotic therapy during pregnancy. Semin Perinatol 2001, 3:165–169.",{"doi":1180},"10.1053\u002Fsper.2001.24899",{"id":20,"text":1182,"url":20,"identifiers":1183},"Hyers TM, Agnelli G, Hull RD, et al.: Antithrombotic therapy for venous thromboembolism. Chest 2001, 119:176S-193S.",{"doi":1184},"10.1378\u002Fchest.119.1_suppl.176S",{"id":20,"text":1186,"url":20,"identifiers":1187},"Hirsh J, Warkentin TE, Shaughnessy SG, et al.: Heparin and low-molecular weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 2001, 119:64S-94S. Good overview of UH and LMWH.",{"doi":1188},"10.1378\u002Fchest.119.1_suppl.64S",{"id":20,"text":1190,"url":20,"identifiers":1191},"Koren G, Pastuszak A, Ito S: Drugs in pregnancy. N Engl J Med 1998, 338:1128–1137.",{"doi":1192},"10.1056\u002FNEJM199804163381607",{"id":20,"text":1194,"url":20,"identifiers":1195},"Bril-Edwards P, Ginsberg JS, Johnston M, Hirsh J: Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993, 119:104–109.",{"doi":1196},"10.7326\u002F0003-4819-119-2-199307150-00002",{"id":20,"text":1198,"url":20,"identifiers":1199},"Leizorovicz A, Simonneau G, Decousus H, Boissel JP: Comparison of efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep vein thrombosis: a meta-analysis. BMJ 1994, 309:299–304.",{"doi":1200},"10.1136\u002Fbmj.309.6950.299",{"id":20,"text":1202,"url":20,"identifiers":1203},"Lensing AW, Prins MH, Davidson BL, Hirsh J: Treatment of deep venous thrombosis with low molecular weight heparins: a meta-analysis. Arch Intern Med 1995, 155:601–607.",{"doi":1204},"10.1001\u002Farchinte.1995.00430060059007",{"id":20,"text":1206,"url":20,"identifiers":1207},"Siragusa S, Cosmi B, Piovella F, et al.: Low-molecularweight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996, 100:269–277.",{"doi":1208},"10.1016\u002FS0002-9343(97)89484-3",{"id":20,"text":1210,"url":20,"identifiers":1211},"Koopman MM, Prandoni P, Piovella F, et al.: Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group. N Engl J Med 1996, 334:682–687.",{"doi":1212},"10.1056\u002FNEJM199603143341102",{"id":20,"text":1214,"url":20,"identifiers":1215},"Dolovich LR, Ginsberg JS, Douketis JD, et al.: A metaanalysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000, 160:181–188.",{"doi":1216},"10.1001\u002Farchinte.160.2.181",{"id":20,"text":1218,"url":20,"identifiers":1219},"Warkentin TE, Levine MN, Hirsh J, et al.: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330–1335.",{"doi":1220},"10.1056\u002FNEJM199505183322003",{"id":20,"text":1222,"url":20,"identifiers":1223},"Muir JM, Andrew M, Hirsh J, et al.: Histomorphometric analysis of the effects of standard heparin on trabecular bone in vivo. Blood 1996, 88:1314–1320.",{"doi":1224},"10.1182\u002Fblood.V88.4.1314.bloodjournal8841314",{"id":20,"text":1226,"url":20,"identifiers":1227},"Muir JM, Hirsh J, Weitz JI, et al.: A histomorphometric comparison of the effects of heparin and low-molecular weight heparin on cancellous bone in rats. Blood 1997, 89:3236–3242.",{"doi":1228},"10.1182\u002Fblood.V89.9.3236",{"id":20,"text":1230,"url":20,"identifiers":1231},"Shaughnessy SG, Hirsh J, Bhandari M, et al.: Histomorphometric evaluation of heparin-induced bone loss after discontinuation of heparin treatment in rats. Blood 1999, 93:1231–1236.",{"doi":1232},"10.1182\u002Fblood.V93.4.1231",{"id":20,"text":1234,"url":20,"identifiers":1235},"Dahlman TC: Osteoporotic fractures and recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993, 168:1265–1270.",{"doi":1236},"10.1016\u002F0002-9378(93)90378-V",{"id":20,"text":1238,"url":20,"identifiers":1239},"Monreal M, Lafoz E, Olive A, et al.: Comparison of subcutaneous unfractionated heparin with a low molecular heparin (Frogman) in patients with venous thromboembolism and contraindications to coumarin. Thromb Haemost 1994, 71:7–11.",{"doi":1240},"10.1055\u002Fs-0038-1642376",{"id":20,"text":1242,"url":20,"identifiers":1243},"Ginsberg JS, Kowalchuk G, Hirsh J, et al.: Heparin effect on bone density. Thromb Haemost 1990, 64:286–289.",{"doi":1244},"10.1055\u002Fs-0038-1647302",{"id":20,"text":1246,"url":20,"identifiers":1247},"Barbour L, Kick SD, Steiner JF, et al.: A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am J Obstet Gynecol 1994, 170:862–869.",{"doi":1248},"10.1016\u002FS0002-9378(94)70299-3",{"id":20,"text":1250,"url":20,"identifiers":1251},"Douketis JD, Ginsberg JS, Burrows R, et al.: The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Hemost 1996, 75:254–257.",{"doi":1252},"10.1055\u002Fs-0038-1650255",{"id":20,"text":1254,"url":20,"identifiers":1255},"Sanson BJ, Lensing AWA, Prins MH, et al.: Safety of lowmolecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999, 81:668–672.",{"doi":1256},"10.1055\u002Fs-0037-1614550",{"id":20,"text":1258,"url":20,"identifiers":1259},"Chan WS, Ray J: Low molecular weight heparin use in pregnancy: issues of safety and practicality. Obstet Gynecol Surv 1999, 54:649–654. Covers relevant, practical areas for the use of LMWH during pregnancy.",{"doi":1260},"10.1097\u002F00006254-199910000-00022",{"id":20,"text":1262,"url":20,"identifiers":1263},"Lindheimer MD, Katz AI: Renal physiology and disease in pregnancy. In The Kidney: Physiology and Pathophysiology. Edited by Sedin DW, Giebisch G. New York: Raven Press; 1992:3371–3431.",{},{"id":20,"text":1265,"url":20,"identifiers":1266},"Ellison J, Walker ID, Greer IA: Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. BJOG 2000, 107:1116–1121.",{"doi":1267},"10.1111\u002Fj.1471-0528.2000.tb11110.x",{"id":20,"text":1269,"url":20,"identifiers":1270},"Brennand JE, Walker ID, Greer IA: Anti-activated factor X profiles in pregnant women receiving antenatal thromboprophylaxis with enoxaparin. Acta Haematol 1999, 101:53–55.",{"doi":1271},"10.1159\u002F000040922",{"id":20,"text":1273,"url":20,"identifiers":1274},"Nelson-Piercy C, Letsky EA, de Swiet M: Low-molecularweight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997, 176:1062–1068.",{"doi":1275},"10.1016\u002FS0002-9378(97)70403-4",{"id":20,"text":1277,"url":20,"identifiers":1278},"Casele HL, Laifer SA, Woelkers DA, Venkataramanan R: Changes in the pharmacokinetics of the low-molecular weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999, 181:1113–1117.",{"doi":1279},"10.1016\u002FS0002-9378(99)70091-8",{"id":20,"text":1281,"url":20,"identifiers":1282},"Forestier F, Daffos F, Capell-Pavlovsky M: Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy. Study by direct fetal blood sampling under ultrasound. Thromb Res 1984, 34:557–560.",{"doi":1283},"10.1016\u002F0049-3848(84)90260-3",{"id":20,"text":1285,"url":20,"identifiers":1286},"Rainaut M, Forestier F, Daffos S, Forestier F: Prenatal pharmacology of LMW heparin and pentosan polysulfate [in French]. J Mal Vasc 1987, 12(suppl):119–122.",{},{"id":20,"text":1288,"url":20,"identifiers":1289},"Forestier F, Daffos F, Rainaut M, Toulemonde F: Low molecular weight heparin (CY 216) does not cross the placenta during the second trimester of pregnancy. Study by direct fetal blood sampling under ultrasound. Thromb Haemost 1987, 57:234.",{"doi":1290},"10.1055\u002Fs-0038-1651102",{"id":20,"text":1292,"url":20,"identifiers":1293},"Omri A, Dellaloye JF, Anderson H, Bachmann F: Low molecular weight heparin novo (LHN-1) does not cross the placenta during the second trimester of pregnancy. Thromb Haemost 1989, 1:55–56.",{},{"id":20,"text":1295,"url":20,"identifiers":1296},"Casele H, Laifer S: Prospective evaluation of bone density changes in pregnant women on low molecular weight heparin [abstract]. Am J Obstet Gynecol 1998, 178:S65.",{},{"id":20,"text":1298,"url":20,"identifiers":1299},"Shefras J, Farquharson RG: Bone density studies in pregnant women receiving heparin. Eur J Obstet Gynecol 1996, 65:171–174.",{"doi":1300},"10.1016\u002F0301-2115(95)02358-5",{"id":20,"text":1302,"url":20,"identifiers":1303},"Backos M, Rai R, Thomas E, et al.: Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. Human Reprod 1999, 14:2876–2880.",{"doi":1304},"10.1093\u002Fhumrep\u002F14.11.2876",{"id":20,"text":1306,"url":20,"identifiers":1307},"Fausett MB, Vogtlander M, Burgett D, et al.: Heparininduced thrombocytopenia is rare in pregnancy. Am J Obstet Gynecol 1998, 178:S66.",{"doi":1308},"10.1016\u002FS0002-9378(98)70629-5",{"id":20,"text":1310,"url":20,"identifiers":1311},"Wutschert R, Piletta P, Bounameaux H: Adverse skin reactions to low molecular weight heparins. Drug Saf 1999, 20:515–525.",{"doi":1312},"10.2165\u002F00002018-199920060-00005",{"id":1314,"createTime":1315,"updateTime":1316,"relativeEntities":1317,"slug":1318,"properties":1319,"entityType":190,"verifyStatus":191,"verifyTime":1330,"verifyNote":193,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":1331,"fullTextUrl":20,"authors":1332,"publicationType":248,"publisherRelationship":1373,"citationCount":1421,"citationInfo":1422,"publishDate":1427,"publishYear":1423,"citationAnalyzeStatus":781,"lastCitationAnalyze":1316,"indexDatabases":1428,"openAccess":20,"references":20,"isForceReanalyzing":692},"3a87a902-46da-4f8b-8118-4d5cb17a8fbe","2024-01-14T08:36:48.147+00:00","2026-07-18T09:03:12.793+00:00",[],"Human-iPS-Cell-Derived-Cardiac-Tissue-Sheets-a-Platform-for-Cardiac-Regeneration",{"abstract":1320,"title":1322,"gsPaper":1324,"references":1326,"doi":1328},{"EN":1321},"Stem cell therapy is a promising therapeutic option for severe cardiac diseases that are resistant to conventional therapies. To overcome the unsatisfactory results of most clinical researches on stem cell injections to an injured heart, we are developing bioengineered cardiac tissue grafts using pluripotent stem cell-derived cardiomyocytes and vascular cells. We have validated the functional benefits of mouse embryonic stem cell-derived and human induced pluripotent stem cell-derived cardiac tissue sheets (CTSs) in a rat myocardial infarction model. We further showed enhanced functional recovery and engraftment efficiency leading to de novo myocardium upon transplanting thick multi-layered CTSs that had gelatin hydrogel microspheres between the layers. We anticipate that the combination of pluripotent stem cell biology and tissue engineering will contribute to future stem cell therapies for severe heart diseases.",{"EN":1323},"Human iPS Cell-Derived Cardiac Tissue Sheets: a Platform for Cardiac Regeneration",{"VOID":1325},"[\"7409560719806980052\"]",{"VOID":1327},"World Health Organization (WHO) Global Health Estimates (GHE): Cause of death, 2000–2012. http:\u002F\u002Fwww.who.int\u002Fhealthinfo\u002Fglobal_burden_disease\u002Festimates\u002Fen\u002Findex1.html.\nBraunwald E, Pfeffer MA. Ventricular enlargement and remodeling following acute myocardial infarction: mechanisms and management. Am J Cardiol. 1991;68(14):1D–6D.\nUygur A, Lee RT. Mechanisms of cardiac regeneration. Dev Cell. 2016;36(4):362–74.\nFisher SA, Doree C, Mathur A, Martin-Rendon E. Meta-analysis of cell therapy trials for patients with heart failure. Circ Res. 2015;116(8):1361–77.\nSchaun MI, Eibel B, Kristocheck M, et al. Cell therapy in ischemic heart disease: interventions that modulate cardiac regeneration. Stem Cells Int. 2016;2016:2171035.\nMenasche P, Vanneaux V, Hagege A, et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur Heart J. 2015. doi:10.1093\u002Feurheartj\u002Fehv189.\nWollert KC, Meyer GP, Lotz J, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet. 2004;364(9429):141–8.\nMeyer GP, Wollert KC, Lotz J, et al. Intracoronary bone marrow cell transfer after myocardial infarction: 5-year follow-up from the randomized-controlled BOOST trial. Eur Heart J. 2009;30(24):2978–84.\nSchachinger V, Erbs S, Elsasser A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med. 2006;355(12):1210–21.\nAssmus B. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation. 2002;106(24):3009–17.\nLeistner DM, Fischer-Rasokat U, Honold J, et al. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI): final 5-year results suggest long-term safety and efficacy. Clin Res Cardiol. 2011;100(10):925–34.\nPerin EC, Willerson JT, Pepine CJ, et al. Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. JAMA. 2012;307(16):1717–26.\nTraverse JH, Henry TD, Pepine CJ, et al. Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. JAMA. 2012;308(22):2380–9.\nTraverse JH, Henry TD, Ellis SG, et al. Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. JAMA. 2011;306(19):2110–9.\nBAMI. The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BM-MNC) on all cause mortality in acute myocardial infarction (BAMI). ClinicalTrials.gov. https:\u002F\u002Fclinicaltrials.gov\u002Fct2\u002Fshow\u002FNCT01569178.\nHeldman AW, DiFede DL, Fishman JE, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy: the TAC-HFT randomized trial. JAMA. 2014;311(1):62–73.\nHare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA. 2012;308(22):2369–79.\nBartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013;61(23):2329–38.\nMenasche P, Alfieri O, Janssens S, et al. The myoblast autologous grafting in ischemic cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation. 2008;117(9):1189–200.\nDib N, Dinsmore J, Lababidi Z, et al. One-year follow-up of feasibility and safety of the first U.S., randomized, controlled study using 3-dimensional guided catheter-based delivery of autologous skeletal myoblasts for ischemic cardiomyopathy (CAuSMIC study). JACC Cardiovasc Interv. 2009;2(1):9–16.\nImamura T, Kinugawa K, Sakata Y, et al. Improved clinical course of autologous skeletal myoblast sheet (TCD-51073) transplantation when compared to a propensity score-matched cardiac resynchronization therapy population. J Artif Organs. 2016;19(1):80–6.\nBolli R, Chugh AR, D’Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378(9806):1847–57.\nThe Lancet E. Expression of concern: the SCIPIO trial. Lancet. 2014;383(9925):1279.\nMakkar RR, Smith RR, Cheng K, et al. Intracoronary cardiosphere-derived cells for heart regeneration after myocardial infarction (CADUCEUS): a prospective, randomised phase 1 trial. Lancet. 2012;379(9819):895–904.\nAutologous human cardiac-derived stem cell to treat ischemic cardiomyopathy (ALCADIA). ClinicalTrials.gov. https:\u002F\u002Fclinicaltrials.gov\u002Fct2\u002Fshow\u002FNCT00981006.\nJoggerst SJ, Hatzopoulos AK. Stem cell therapy for cardiac repair: benefits and barriers. Exp Rev Mol Med. 2009;11:e20.\nMuller-Ehmsen J, Whittaker P, Kloner RA, et al. Survival and development of neonatal rat cardiomyocytes transplanted into adult myocardium. J Mol Cell Cardiol. 2002;34(2):107–16.\nTeng CJ, Luo J, Chiu RCJ, Shum-Tim D. Massive mechanical loss of microspheres with direct intramyocardial injection in the beating heart: implications for cellular cardiomyoplasty. J Thorac Cardiovasc Surg. 2006;132(3):628–32.\nMadonna R, Van Laake LW, Davidson SM, et al. Position paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. Eur Heart J. 2016;37(23):1789–98.\nYe L, Zimmermann WH, Garry DJ, Zhang J. Patching the heart: cardiac repair from within and outside. Circ Res. 2013;113(7):922–32.\nThomson JA. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145–7.\nTakahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–76.\nTakahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131(5):861–72.\nMurry CE, Keller G. Differentiation of embryonic stem cells to clinically relevant populations: lessons from embryonic development. Cell. 2008;132(4):661–80.\nMasumoto H, Sakata R. Cardiovascular surgery for realization of regenerative medicine. Gen Thorac Cardiovasc Surg. 2012;60(11):744–55.\nYamashita J, Itoh H, Hirashima M, et al. Flk1-positive cells derived from embryonic stem cells serve as vascular progenitors. Nature. 2000;408(6808):92–6.\nYamashita JK, Takano M, Hiraoka-Kanie M, et al. Prospective identification of cardiac progenitors by a novel single cell-based cardiomyocyte induction. FASEB J. 2005;19(9):1534–6.\nMasumoto H, Ikuno T, Takeda M, et al. Human iPS cell-engineered cardiac tissue sheets with cardiomyocytes and vascular cells for cardiac regeneration. Sci Rep. 2014;4:6716. This article shows that the cell sheet consisted of human iPS cell-derived cardiovascular cells including cardiomyocytes and vascular cells can improve cardiac dysfunction after myocardial infarction and regenerate myocardium into an injured heart.\nSone M, Itoh H, Yamahara K, et al. Pathway for differentiation of human embryonic stem cells to vascular cell components and their potential for vascular regeneration. Arterioscler Thromb Vasc Biol. 2007;27(10):2127–34.\nLian X, Hsiao C, Wilson G, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci U S A. 2012;109(27):E1848–1857.\nChen VC, Ye J, Shukla P, et al. Development of a scalable suspension culture for cardiac differentiation from human pluripotent stem cells. Stem Cell Res. 2015;15(2):365–75.\nvan Laake LW, Passier R, Monshouwer-Kloots J, et al. Human embryonic stem cell-derived cardiomyocytes survive and mature in the mouse heart and transiently improve function after myocardial infarction. Stem Cell Res. 2007;1(1):9–24.\nMasumoto H, Matsuo T, Yamamizu K, et al. Pluripotent stem cell-engineered cell sheets reassembled with defined cardiovascular populations ameliorate reduction in infarct heart function through cardiomyocyte-mediated neovascularization. Stem Cells. 2012;30(6):1196–205. This article indicates that mouse embryonic stem cell-derived cardiac sheet including cardiomyocytes, vascular endothelial and mural cells ameliorates cardiac dysfunction after myocardiac infarction of a rat. This article also shows that cardiomyocytes are indispensable for cardiac stem cell therapy through neovascularization.\nNarazaki G, Uosaki H, Teranishi M, et al. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation. 2008;118(5):498–506.\nOkita K, Matsumura Y, Sato Y, et al. A more efficient method to generate integration-free human iPS cells. Nat Methods. 2011;8(5):409–12.\nCortes-Morichetti M, Frati G, Schussler O, et al. Association between a cell-seeded collagen matrix and cellular cardiomyoplasty for myocardial support and regeneration. Tissue Eng. 2007;13(11):2681–7.\nChristman KL, Lee RJ. Biomaterials for the treatment of myocardial infarction. J Am Coll Cardiol. 2006;48(5):907–13.\nStevens KR, Kreutziger KL, Dupras SK, et al. Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proc Natl Acad Sci U S A. 2009;106(39):16568–73.\nOkano T, Yamada N, Sakai H, Sakurai Y. A novel recovery-system for cultured-cells using plasma-treated polystyrene dishes grafted with Poly(N-Isopropylacrylamide). J Biomed Mater Res. 1993;27(10):1243–51.\nMiyahara Y, Nagaya N, Kataoka M, et al. Monolayered mesenchymal stem cells repair scarred myocardium after myocardial infarction. Nat Med. 2006;12(4):459–65.\nChang D, Wen Z, Wang Y, et al. Ultrastructural features of ischemic tissue following application of a bio-membrane based progenitor cardiomyocyte patch for myocardial infarction repair. PLoS One. 2014;9(10):e107296.\nLaflamme MA, Chen KY, Naumova AV, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol. 2007;25(9):1015–24.\nUosaki H, Fukushima H, Takeuchi A, et al. Efficient and scalable purification of cardiomyocytes from human embryonic and induced pluripotent stem cells by VCAM1 surface expression. PLoS One. 2011;6(8):e23657.\nShimizu T, Yamato M, Isoi Y, et al. Fabrication of pulsatile cardiac tissue grafts using a novel 3-dimensional cell sheet manipulation technique and temperature-responsive cell culture surfaces. Circ Res. 2002;90(3):E40–8.\nShimizu T, Sekine H, Yang J, et al. Polysurgery of cell sheet grafts overcomes diffusion limits to produce thick, vascularized myocardial tissues. FASEB J. 2006;20(6):708–10.\nHayashi K, Tabata Y. Preparation of stem cell aggregates with gelatin microspheres to enhance biological functions. Acta Biomater. 2011;7(7):2797–803.\nMatsuo T, Masumoto H, Tajima S, et al. Efficient long-term survival of cell grafts after myocardial infarction with thick viable cardiac tissue entirely from pluripotent stem cells. Sci Rep. 2015;5:16842. This article indicates that thick layering of cardiac tissue sheets using gelatin hydrogel microspheres enables to generate thick layered cardiac tissue sheet and the transplantation to a rat myocardial infarction model further enhances functional recovery and myocardial regeneration as a de novo myocardium.\nSakaguchi K, Shimizu T, Horaguchi S, et al. In vitro engineering of vascularized tissue surrogates. Sci Rep. 2013;3:1316.",{"VOID":1329},"10.1007\u002Fs11936-016-0489-z","2024-06-23T18:55:50.585+00:00","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11936-016-0489-z",[1333,1358],{"id":1334,"sortIndex":21,"researcher":20,"roles":1335,"affiliations":1336,"properties":1353,"displayName":1355,"givenName":20,"familyName":20},"ee82dddc-ed85-4772-b193-433e81b7866d",[716],[1337,1345],{"id":1338,"sortIndex":21,"affiliation":1339,"properties":20},"d3e59610-c334-4b92-ba99-f2634142b342",{"id":1338,"createTime":20,"updateTime":20,"relativeEntities":1340,"slug":20,"properties":1341,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1344,"statistic":20},[],{"title":1342},{"VI":1343},"Department of Stem Cell Growth and Differentiation, Center for iPS Cell Research and Application (CiRA), Kyoto University, Sakyo-ku, Japan",[],{"id":1346,"sortIndex":219,"affiliation":1347,"properties":20},"1e25e951-62d5-47b6-8b7d-cccacb56a681",{"id":1346,"createTime":20,"updateTime":20,"relativeEntities":1348,"slug":20,"properties":1349,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1352,"statistic":20},[],{"title":1350},{"VI":1351},"Department of Cardiovascular Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan",[],{"title":1354,"gsAuthor":1356},{"VI":1355},"Hidetoshi Masumoto",{"VOID":1357},"[\"HBdnBEEAAAAJ\"]",{"id":1359,"sortIndex":219,"researcher":20,"roles":1360,"affiliations":1361,"properties":1368,"displayName":1370,"givenName":20,"familyName":20},"291b937e-4dfa-4a34-9ae4-442652a39f38",[716],[1362],{"id":1338,"sortIndex":21,"affiliation":1363,"properties":20},{"id":1338,"createTime":20,"updateTime":20,"relativeEntities":1364,"slug":20,"properties":1365,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1367,"statistic":20},[],{"title":1366},{"VI":1343},[],{"title":1369,"gsAuthor":1371},{"VI":1370},"Jun K. Yamashita",{"VOID":1372},"[\"VdwQVlgAAAAJ\"]",{"url":1331,"publisher":1374,"properties":1416},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1375,"slug":10,"properties":1376,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":1380,"manageAffiliations":1385,"indexDatabases":1396,"url":20,"thumbnailPath":20,"statistic":1411,"gsStatistic":20,"type":20,"analyzePriority":20},[],{"issn":1377,"title":1378,"eissn":1379},{"VOID":13},{"EN":15},{"VOID":17},[1381],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":1382,"label":1383,"description":1384,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},[1386,1391],{"id":31,"createTime":20,"updateTime":20,"relativeEntities":1387,"slug":20,"properties":1388,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1390,"statistic":20},[],{"title":1389},{"EN":35},[37],{"id":39,"createTime":20,"updateTime":20,"relativeEntities":1392,"slug":20,"properties":1393,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1395,"statistic":20},[],{"title":1394},{"EN":43},[],[1397,1404],{"id":47,"indexDatabase":1398,"url":58,"indexYears":59,"academicFieldIds":1403,"indexDatabaseRanking":62},{"id":49,"createTime":20,"updateTime":20,"relativeEntities":1399,"label":1400,"description":1401,"key":55,"publicationTags":1402,"standard":20},[],{"EN":52,"VI":52},{"EN":52,"VI":54},[57],[61],{"id":64,"indexDatabase":1405,"url":77,"indexYears":20,"academicFieldIds":1410,"indexDatabaseRanking":20},{"id":66,"createTime":20,"updateTime":20,"relativeEntities":1406,"label":1407,"description":1408,"key":73,"publicationTags":1409,"standard":20},[],{"EN":69,"VI":69},{"EN":71,"VI":72},[75,76],[79],{"impactFactor":21,"impactFactorByYear":1412,"i10Index":93,"i10IndexLast5Year":94,"totalPublication":95,"totalPublicationByYear":1413,"totalCitation":121,"totalCitationByYear":1414,"totalCitationPerPublication":141,"totalCitationPerPublicationByYear":1415,"hindexLast5Year":166,"hindex":166},{"2012":82,"2013":83,"2014":83,"2015":84,"2016":85,"2017":86,"2018":87,"2019":88,"2020":89,"2021":90,"2022":91,"2023":92},{"1999":97,"2000":98,"2001":99,"2002":100,"2003":101,"2004":102,"2005":103,"2006":104,"2007":105,"2008":106,"2009":107,"2010":108,"2011":109,"2012":109,"2013":108,"2014":110,"2015":111,"2016":112,"2017":113,"2018":114,"2019":115,"2020":116,"2021":117,"2022":118,"2023":119,"2024":120},{"1999":123,"2000":109,"2001":124,"2002":125,"2003":126,"2004":127,"2005":112,"2006":128,"2007":129,"2008":130,"2009":113,"2010":131,"2011":132,"2012":133,"2013":93,"2014":134,"2015":135,"2016":136,"2017":137,"2018":113,"2019":138,"2020":97,"2021":139,"2023":140},{"1999":143,"2000":144,"2001":145,"2002":146,"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2010":154,"2011":155,"2012":156,"2013":141,"2014":157,"2015":158,"2016":159,"2017":160,"2018":161,"2019":162,"2020":163,"2021":164,"2023":165},{"pages":1417,"volume":1419},{"VOID":1418},"1-10",{"VOID":1420},"18",23,{"total":1421,"publishYear":1423,"statisticByYear":1424},2016,{"2016":219,"2017":1425,"2018":1426,"2019":140,"2020":140,"2021":219,"2023":120,"2025":1426,"2026":219},5,3,"2016-09-16",[62,75],{"id":1430,"createTime":1431,"updateTime":1432,"relativeEntities":1433,"slug":1434,"properties":1435,"entityType":190,"verifyStatus":191,"verifyTime":1445,"verifyNote":193,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":1446,"fullTextUrl":20,"authors":1447,"publicationType":248,"publisherRelationship":1478,"citationCount":20,"citationInfo":20,"publishDate":1526,"publishYear":1527,"citationAnalyzeStatus":297,"lastCitationAnalyze":1528,"indexDatabases":1529,"openAccess":20,"references":20,"isForceReanalyzing":692},"455f064e-a157-4b29-814b-8bf01f9cf69f","2023-11-29T15:23:07.106+00:00","2026-07-13T21:01:57.660+00:00",[],"Left-Atrial-Electroanatomical-Voltage-Mapping-to-Characterize-Substrate-and-Guide-Ablation",{"abstract":1436,"title":1438,"gsPaper":1440,"references":1441,"doi":1443},{"EN":1437},"Despite enthusiasm for catheter ablation of atrial fibrillation, procedural outcomes are less robust when compared to other atrial arrhythmias Adverse atrial remodeling is associated with both the perpetuation of atrial fibrillation as well as decreased responsiveness to restorative therapies. However, characterization of remodeling has historically relied on demographic factors and echocardiographic imaging which provide inadequate insight into the pattern and distribution of atrial fibrosis. Advancements in electroanatomical mapping allow rapid collection of dense three-dimensional maps that display both structural and functional datasets. The purpose of this review is to discuss contemporary studies that seek to determine bipolar electrogram characteristics in patients with and without atrial fibrillation. We will also review studies that use electrogram data to guide substrate-based ablation in AF patients.",{"EN":1439},"Left Atrial Electroanatomical Voltage Mapping to Characterize Substrate and Guide Ablation",{"VOID":185},{"VOID":1442},"Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2019 update: a report from the American Heart Association. Circulation. 2019:CIR0000000000000659. https:\u002F\u002Fdoi.org\u002F10.1161\u002FCIR.0000000000000659.\nKirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893–962. https:\u002F\u002Fdoi.org\u002F10.1093\u002Feurheartj\u002Fehw210.\nJanuary CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA\u002FACC\u002FHRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology\u002FAmerican Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014;64(21):e1–76. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jacc.2014.03.022.\nCalkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L, et al. 2017 HRS\u002FEHRA\u002FECAS\u002FAPHRS\u002FSOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14(10):e275–444. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.hrthm.2017.05.012.\nKuck KH, Brugada J, Furnkranz A, Metzner A, Ouyang F, Chun KR, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med. 2016;374(23):2235–45. https:\u002F\u002Fdoi.org\u002F10.1056\u002FNEJMoa1602014.\nKawai S, Mukai Y, Inoue S, Yakabe D, Nagaoka K, Sakamoto K, et al. Non-pulmonary vein triggers of atrial fibrillation are likely to arise from low-voltage areas in the left atrium. Sci Rep. 2019;9(1):12271. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41598-019-48669-1.\nChen LY, Chung MK, Allen LA, Ezekowitz M, Furie KL, McCabe P, et al. Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a scientific statement from the American Heart Association. Circulation. 2018;137(20):e623–e44. https:\u002F\u002Fdoi.org\u002F10.1161\u002FCIR.0000000000000568.\nVerma A, Jiang CY, Betts TR, Chen J, Deisenhofer I, Mantovan R, et al. Approaches to catheter ablation for persistent atrial fibrillation. N Engl J Med. 2015;372(19):1812–22. https:\u002F\u002Fdoi.org\u002F10.1056\u002FNEJMoa1408288.\nMarrouche NF, Wilber D, Hindricks G, Jais P, Akoum N, Marchlinski F, et al. Association of atrial tissue fibrosis identified by delayed enhancement MRI and atrial fibrillation catheter ablation: the DECAAF study. JAMA. 2014;311(5):498–506. https:\u002F\u002Fdoi.org\u002F10.1001\u002Fjama.2014.3.\nSiebermair J, Kholmovski EG, Marrouche N. Assessment of left atrial fibrosis by late gadolinium enhancement magnetic resonance imaging: methodology and clinical implications. JACC Clin Electrophysiol. 2017;3(8):791–802. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jacep.2017.07.004.\nMcGann C, Akoum N, Patel A, Kholmovski E, Revelo P, Damal K, et al. Atrial fibrillation ablation outcome is predicted by left atrial remodeling on MRI. Circ Arrhythm Electrophysiol. 2014;7(1):23–30. https:\u002F\u002Fdoi.org\u002F10.1161\u002Fcircep.113.000689.\nNjoku A, Kannabhiran M, Arora R, Reddy P, Gopinathannair R, Lakkireddy D, et al. Left atrial volume predicts atrial fibrillation recurrence after radiofrequency ablation: a meta-analysis. Europace. 2018;20(1):33–42. https:\u002F\u002Fdoi.org\u002F10.1093\u002Feuropace\u002Feux013.\nBadano LP, Miglioranza MH, Mihaila S, Peluso D, Xhaxho J, Marra MP, et al. Left atrial volumes and function by three-dimensional echocardiography: reference values, accuracy, reproducibility, and comparison with two-dimensional echocardiographic measurements. Circ Cardiovasc Imaging. 2016;9(7). https:\u002F\u002Fdoi.org\u002F10.1161\u002FCIRCIMAGING.115.004229.\nKottkamp H, Berg J, Bender R, Rieger A, Schreiber D. Box isolation of fibrotic areas (BIFA): a patient-tailored substrate modification approach for ablation of atrial fibrillation. J Cardiovasc Electrophysiol. 2016;27(1):22–30. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fjce.12870.\nSchotten U, Verheule S, Kirchhof P, Goette A. Pathophysiological mechanisms of atrial fibrillation: a translational appraisal. Physiol Rev. 2011;91(1):265–325. https:\u002F\u002Fdoi.org\u002F10.1152\u002Fphysrev.00031.2009.\nGuichard JB, Nattel S. Atrial cardiomyopathy: a useful notion in cardiac disease management or a passing fad? J Am Coll Cardiol. 2017;70(6):756–65. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jacc.2017.06.033.\nNattel S, Harada M. Atrial remodeling and atrial fibrillation: recent advances and translational perspectives. J Am Coll Cardiol. 2014;63(22):2335–45. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jacc.2014.02.555.\nPlatonov PG, Mitrofanova LB, Orshanskaya V, Ho SY. Structural abnormalities in atrial walls are associated with presence and persistency of atrial fibrillation but not with age. J Am Coll Cardiol. 2011;58(21):2225–32. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jacc.2011.05.061.\nGoette A, Kalman JM, Aguinaga L, Akar J, Cabrera JA, Chen SA, et al. EHRA\u002FHRS\u002FAPHRS\u002FSOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication. Heart Rhythm. 2017;14(1):e3–e40. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.hrthm.2016.05.028.\nJadidi AS, Cochet H, Shah AJ, Kim SJ, Duncan E, Miyazaki S, et al. Inverse relationship between fractionated electrograms and atrial fibrosis in persistent atrial fibrillation: combined magnetic resonance imaging and high-density mapping. J Am Coll Cardiol. 2013;62(9):802–12. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jacc.2013.03.081.\nEckstein J, Maesen B, Linz D, Zeemering S, van Hunnik A, Verheule S, et al. Time course and mechanisms of endo-epicardial electrical dissociation during atrial fibrillation in the goat. Cardiovasc Res. 2011;89(4):816–24. https:\u002F\u002Fdoi.org\u002F10.1093\u002Fcvr\u002Fcvq336.\nMesquita TRR, Zhang R, de Couto G, Valle J, Sanchez L, Rogers RG, et al. Mechanisms of atrial fibrillation in aged rats with heart failure with preserved ejection fraction. Heart Rhythm. 2020;17(6):1025–33. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.hrthm.2020.02.007.\nSanders P, Morton JB, Davidson NC, Spence SJ, Vohra JK, Sparks PB, et al. Electrical remodeling of the atria in congestive heart failure. Circulation. 2003;108(12):1461–8. https:\u002F\u002Fdoi.org\u002F10.1161\u002F01.CIR.0000090688.49283.67.\nOliver W, Matthews G, Ayers CR, Garg S, Gupta S, Neeland IJ, et al. Factors associated with left atrial remodeling in the general population. Circ Cardiovasc Imaging. 2017;10(2). https:\u002F\u002Fdoi.org\u002F10.1161\u002FCIRCIMAGING.116.005047.\nCosta FM, Ferreira AM, Oliveira S, Santos PG, Durazzo A, Carmo P, et al. Left atrial volume is more important than the type of atrial fibrillation in predicting the long-term success of catheter ablation. Int J Cardiol. 2015;184:56–61. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ijcard.2015.01.060.\nMahajan R, Lau DH, Brooks AG, Shipp NJ, Manavis J, Wood JP, et al. Electrophysiological, electroanatomical, and structural remodeling of the atria as consequences of sustained obesity. J Am Coll Cardiol. 2015;66(1):1–11. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jacc.2015.04.058.\nPathak RK, Middeldorp ME, Meredith M, Mehta AB, Mahajan R, Wong CX, et al. Long-term effect of goal-directed weight management in an atrial fibrillation cohort: a long-term follow-up study (LEGACY). J Am Coll Cardiol. 2015;65(20):2159–69. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jacc.2015.03.002.\nPark JH, Pak HN, Choi EJ, Jang JK, Kim SK, Choi DH, et al. The relationship between endocardial voltage and regional volume in electroanatomical remodeled left atria in patients with atrial fibrillation: comparison of three-dimensional computed tomographic images and voltage mapping. J Cardiovasc Electrophysiol. 2009;20(12):1349–56. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fj.1540-8167.2009.01557.x.\nGal P, Marrouche NF. Magnetic resonance imaging of atrial fibrosis: redefining atrial fibrillation to a syndrome. Eur Heart J. 2017;38(1):14–9. https:\u002F\u002Fdoi.org\u002F10.1093\u002Feurheartj\u002Fehv514.\nMulder MJ, Kemme MJB, Visser CL, Hopman L, van Diemen PA, van de Ven PM, et al. Left atrial sphericity as a marker of atrial remodeling: comparison of atrial fibrillation patients and controls. Int J Cardiol. 2020;304:69–74. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ijcard.2020.01.042.\nYamashita K, Silvernagel J, Kwan E, Kamali R, Ghafoori E, MacLeod R, et al. Changes in atrial electrophysiological and structural substrate and their relationship to histology in a long-term chronic canine atrial fibrillation model. Pacing Clin Electrophysiol. 2019;42(7):930–6. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fpace.13730.\nPark J, Joung B, Uhm JS, Young Shim C, Hwang C, Hyoung Lee M, et al. High left atrial pressures are associated with advanced electroanatomical remodeling of left atrium and independent predictors for clinical recurrence of atrial fibrillation after catheter ablation. Heart Rhythm. 2014;11(6):953–60. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.hrthm.2014.03.009.\nWalters TE, Nisbet A, Morris GM, Tan G, Mearns M, Teo E, et al. Progression of atrial remodeling in patients with high-burden atrial fibrillation: implications for early ablative intervention. Heart Rhythm. 2016;13(2):331–9. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.hrthm.2015.10.028.\nSpragg DD, Khurram I, Zimmerman SL, Yarmohammadi H, Barcelon B, Needleman M, et al. Initial experience with magnetic resonance imaging of atrial scar and co-registration with electroanatomic voltage mapping during atrial fibrillation: success and limitations. Heart Rhythm. 2012;9(12):2003–9. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.hrthm.2012.08.039.\nJosephson ME, Anter E. Substrate mapping for ventricular tachycardia: assumptions and misconceptions. JACC Clin Electrophysiol. 2015;1(5):341–52. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jacep.2015.09.001.\nHutchinson MD, Gerstenfeld EP, Desjardins B, Bala R, Riley MP, Garcia FC, et al. Endocardial unipolar voltage mapping to detect epicardial ventricular tachycardia substrate in patients with nonischemic left ventricular cardiomyopathy. Circ Arrhythm Electrophysiol. 2011;4(1):49–55. https:\u002F\u002Fdoi.org\u002F10.1161\u002FCIRCEP.110.959957.\nNedios S, Sommer P, Bollmann A, Hindricks G. Advanced mapping systems to guide atrial fibrillation ablation: electrical information that matters. J Atr Fibrillation. 2016;8(6):1337. https:\u002F\u002Fdoi.org\u002F10.4022\u002Fjafib.1337.\nAnter E, Josephson ME. Bipolar voltage amplitude: what does it really mean? Heart Rhythm. 2016;13(1):326–7. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.hrthm.2015.09.033.\nLin Y, Yang B, Garcia FC, Ju W, Zhang F, Chen H, et al. Comparison of left atrial electrophysiologic abnormalities during sinus rhythm in patients with different type of atrial fibrillation. J Interv Card Electrophysiol. 2014;39(1):57–67. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs10840-013-9838-y.\nYang G, Yang B, Wei Y, Zhang F, Ju W, Chen H, et al. Catheter ablation of nonparoxysmal atrial fibrillation using electrophysiologically guided substrate modification during sinus rhythm after pulmonary vein isolation. Circ Arrhythm Electrophysiol. 2016;9(2):e003382. https:\u002F\u002Fdoi.org\u002F10.1161\u002FCIRCEP.115.003382.\nTeh AW, Kistler PM, Lee G, Medi C, Heck PM, Spence SJ, et al. Long-term effects of catheter ablation for lone atrial fibrillation: progressive atrial electroanatomic substrate remodeling despite successful ablation. Heart Rhythm. 2012;9(4):473–80. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.hrthm.2011.11.013.\nTeh AW, Kistler PM, Lee G, Medi C, Heck PM, Spence SJ, et al. Electroanatomic remodeling of the left atrium in paroxysmal and persistent atrial fibrillation patients without structural heart disease. J Cardiovasc Electrophysiol. 2012;23(3):232–8. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fj.1540-8167.2011.02178.x.\nAnter E, Tschabrunn CM, Josephson ME. High-resolution mapping of scar-related atrial arrhythmias using smaller electrodes with closer interelectrode spacing. Circ Arrhythm Electrophysiol. 2015;8(3):537–45. https:\u002F\u002Fdoi.org\u002F10.1161\u002FCIRCEP.114.002737.\nKornej J, Schumacher K, Dinov B, Kosich F, Sommer P, Arya A, et al. Prediction of electro-anatomical substrate and arrhythmia recurrences using APPLE, DR-FLASH and MB-LATER scores in patients with atrial fibrillation undergoing catheter ablation. Sci Rep. 2018;8(1):12686. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fs41598-018-31133-x.\nSaghy L, Callans DJ, Garcia F, Lin D, Marchlinski FE, Riley M, et al. Is there a relationship between complex fractionated atrial electrograms recorded during atrial fibrillation and sinus rhythm fractionation? Heart Rhythm. 2012;9(2):181–8. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.hrthm.2011.09.062.\nde Groot NM, Schalij MJ, Zeppenfeld K, Blom NA, Van der Velde ET, Van der Wall EE. Voltage and activation mapping: how the recording technique affects the outcome of catheter ablation procedures in patients with congenital heart disease. Circulation. 2003;108(17):2099–106. https:\u002F\u002Fdoi.org\u002F10.1161\u002F01.CIR.0000092893.11893.38.\nRolf S, Kircher S, Arya A, Eitel C, Sommer P, Richter S, et al. Tailored atrial substrate modification based on low-voltage areas in catheter ablation of atrial fibrillation. Circ Arrhythm Electrophysiol. 2014;7(5):825–33. https:\u002F\u002Fdoi.org\u002F10.1161\u002FCIRCEP.113.001251.\nZhou W, Wang L, Zhou B, Wu L. Catheter ablation of paroxysmal atrial fibrillation using high-density mapping-guided substrate modification. Pacing Clin Electrophysiol. 2018. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fpace.13524.\nYang B, Jiang C, Lin Y, Yang G, Chu H, Cai H, et al. STABLE-SR (Electrophysiological Substrate Ablation in the Left Atrium During Sinus Rhythm) for the treatment of nonparoxysmal atrial fibrillation: a prospective, multicenter randomized clinical trial. Circ Arrhythm Electrophysiol. 2017;10(11). https:\u002F\u002Fdoi.org\u002F10.1161\u002Fcircep.117.005405.\nMasuda M, Fujita M, Iida O, Okamoto S, Ishihara T, Nanto K, et al. Left atrial low-voltage areas predict atrial fibrillation recurrence after catheter ablation in patients with paroxysmal atrial fibrillation. Int J Cardiol. 2018;257:97–101. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ijcard.2017.12.089.\nBegg GA, Karim R, Oesterlein T, Graham LN, Hogarth AJ, Page SP, et al. Left atrial voltage, circulating biomarkers of fibrosis, and atrial fibrillation ablation. A prospective cohort study. PLoS One. 2018;13(1):e0189936. https:\u002F\u002Fdoi.org\u002F10.1371\u002Fjournal.pone.0189936.\nVerma A, Wazni OM, Marrouche NF, Martin DO, Kilicaslan F, Minor S, et al. Pre-existent left atrial scarring in patients undergoing pulmonary vein antrum isolation: an independent predictor of procedural failure. J Am Coll Cardiol. 2005;45(2):285–92. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jacc.2004.10.035.\nHuo Y, Gaspar T, Pohl M, Sitzy J, Richter U, Neudeck S, et al. Prevalence and predictors of low voltage zones in the left atrium in patients with atrial fibrillation. Europace. 2018;20(6):956–62. https:\u002F\u002Fdoi.org\u002F10.1093\u002Feuropace\u002Feux082.\nJadidi AS, Lehrmann H, Keyl C, Sorrel J, Markstein V, Minners J, et al. Ablation of persistent atrial fibrillation targeting low-voltage areas with selective activation characteristics. Circ Arrhythm Electrophysiol. 2016;9(3). https:\u002F\u002Fdoi.org\u002F10.1161\u002FCIRCEP.115.002962.\nWang XH, Li Z, Mao JL, He B. A novel individualized substrate modification approach for the treatment of long-standing persistent atrial fibrillation: preliminary results. Int J Cardiol. 2014;175(1):162–8. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ijcard.2014.05.022.\nKircher S, Arya A, Altmann D, Rolf S, Bollmann A, Sommer P, et al. Individually tailored vs. standardized substrate modification during radiofrequency catheter ablation for atrial fibrillation: a randomized study. Europace. 2018;20(11):1766–75. https:\u002F\u002Fdoi.org\u002F10.1093\u002Feuropace\u002Feux310.\nAmmar-Busch S, Buiatti A, Tatzber A, Reents T, Bourier F, Semmler V, et al. Predictors of low voltage areas in persistent atrial fibrillation: is it really a matter of time? J Interv Card Electrophysiol. 2018. https:\u002F\u002Fdoi.org\u002F10.1007\u002Fs10840-018-0471-7.\nCutler MJ, Johnson J, Abozguia K, Rowan S, Lewis W, Costantini O, et al. Impact of voltage mapping to guide whether to perform ablation of the posterior wall in patients with persistent atrial fibrillation. J Cardiovasc Electrophysiol. 2016;27(1):13–21. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fjce.12830.\nYagishita A, DEO S, Cakulev I, Gimbel JR, Sparano D, Manyam H, et al. Correlation of left atrial voltage distribution between sinus rhythm and atrial fibrillation: identifying structural remodeling by 3-D electroanatomic mapping irrespective of the rhythm. J Cardiovasc Electrophysiol. 2016;27(8):905–12. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fjce.13002.\nRodriguez-Manero M, Valderrabano M, Baluja A, Kreidieh O, Martinez-Sande JL, Garcia-Seara J, et al. Validating left atrial low voltage areas during atrial fibrillation and atrial flutter using multielectrode automated electroanatomic mapping. JACC Clin Electrophysiol. 2018;4(12):1541–52. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jacep.2018.08.015.\nQureshi NA, Kim SJ, Cantwell CD, Afonso VX, Bai W, Ali RL, et al. Voltage during atrial fibrillation is superior to voltage during sinus rhythm in localizing areas of delayed enhancement on magnetic resonance imaging: an assessment of the posterior left atrium in patients with persistent atrial fibrillation. Heart Rhythm. 2019;16(9):1357–67. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.hrthm.2019.05.032.\nMiyamoto K, Tsuchiya T, Narita S, Yamaguchi T, Nagamoto Y, Ando S, et al. Bipolar electrogram amplitudes in the left atrium are related to local conduction velocity in patients with atrial fibrillation. Europace. 2009;11(12):1597–605. https:\u002F\u002Fdoi.org\u002F10.1093\u002Feuropace\u002Feup352.\nNademanee K, McKenzie J, Kosar E, Schwab M, Sunsaneewitayakul B, Vasavakul T, et al. A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate. J Am Coll Cardiol. 2004;43(11):2044–53. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jacc.2003.12.054.\nSeitz J, Bars C, Théodore G, Beurtheret S, Lellouche N, Bremondy M, et al. AF ablation guided by spatiotemporal electrogram dispersion without pulmonary vein isolation: a wholly patient-tailored approach. J Am Coll Cardiol. 2017;69(3):303–21. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jacc.2016.10.065.\nTakahashi Y, O'Neill MD, Hocini M, Dubois R, Matsuo S, Knecht S, et al. Characterization of electrograms associated with termination of chronic atrial fibrillation by catheter ablation. J Am Coll Cardiol. 2008;51(10):1003–10. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jacc.2007.10.056.\nEfremidis M, Vlachos K, Letsas KP, Bazoukis G, Martin R, Frontera A, et al. Targeted ablation of specific electrogram patterns in low-voltage areas after pulmonary vein antral isolation in persistent atrial fibrillation: termination to an organized rhythm reduces atrial fibrillation recurrence. J Cardiovasc Electrophysiol. 2019;30(1):47–57. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fjce.13763.\nChang SL, Tai CT, Lin YJ, Wongcharoen W, Lo LW, Tuan TC, et al. Biatrial substrate properties in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2007;18(11):1134–9. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fj.1540-8167.2007.00941.x.\nWatanabe Y, Nakano Y, Hidaka T, Oda N, Kajihara K, Tokuyama T, et al. Mechanical and substrate abnormalities of the left atrium assessed by 3-dimensional speckle-tracking echocardiography and electroanatomic mapping system in patients with paroxysmal atrial fibrillation. Heart Rhythm. 2015;12(3):490–7. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.hrthm.2014.12.007.\nKistler PM, Sanders P, Fynn SP, Stevenson IH, Spence SJ, Vohra JK, et al. Electrophysiologic and electroanatomic changes in the human atrium associated with age. J Am Coll Cardiol. 2004;44(1):109–16. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jacc.2004.03.044.\nVlachos K, Efremidis M, Letsas KP, Bazoukis G, Martin R, Kalafateli M, et al. Low-voltage areas detected by high-density electroanatomical mapping predict recurrence after ablation for paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 2017;28(12):1393–402. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fjce.13321.\nSung SH, Chang SL, Hsu TL, Yu WC, Tai CT, Lin YJ, et al. Do the left atrial substrate properties correlate with the left atrial mechanical function? A novel insight from the electromechanical study in patients with atrial fibrillation. J Cardiovasc Electrophysiol. 2008;19(2):165–71. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fj.1540-8167.2007.00982.x.\nCorradi D, Callegari S, Manotti L, Ferrara D, Goldoni M, Alinovi R, et al. Persistent lone atrial fibrillation: clinicopathologic study of 19 cases. Heart Rhythm. 2014;11(7):1250–8. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.hrthm.2014.02.008.\nAnter E, Di Biase L, Contreras-Valdes FM, Gianni C, Mohanty S, Tschabrunn CM, et al. Atrial substrate and triggers of paroxysmal atrial fibrillation in patients with obstructive sleep apnea. Circ Arrhythm Electrophysiol. 2017;10(11). https:\u002F\u002Fdoi.org\u002F10.1161\u002FCIRCEP.117.005407.\nYamaguchi T, Tsuchiya T, Fukui A, Kawano Y, Otsubo T, Takahashi Y, et al. Impact of the extent of low-voltage zone on outcomes after voltage-based catheter ablation for persistent atrial fibrillation. J Cardiol. 2018;72(5):427–33. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jjcc.2018.04.010.\nMahnkopf C, Badger TJ, Burgon NS, Daccarett M, Haslam TS, Badger CT, et al. Evaluation of the left atrial substrate in patients with lone atrial fibrillation using delayed-enhanced MRI: implications for disease progression and response to catheter ablation. Heart Rhythm. 2010;7(10):1475–81. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.hrthm.2010.06.030.\nHuang D, Li JB, Zghaib T, Gucuk Ipek E, Balouch M, Spragg DD, et al. The extent of left atrial low-voltage areas included in pulmonary vein isolation is associated with freedom from recurrent atrial arrhythmia. Can J Cardiol. 2018;34(1):73–9. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.cjca.2017.10.012.\nBlandino A, Bianchi F, Grossi S, Biondi-Zoccai G, Conte MR, Gaido L, et al. Left atrial substrate modification targeting low-voltage areas for catheter ablation of atrial fibrillation: a systematic review and meta-analysis. Pacing Clin Electrophysiol. 2017;40(2):199–212. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fpace.13015.\nKottkamp H, Bender R, Berg J. Catheter ablation of atrial fibrillation: how to modify the substrate? J Am Coll Cardiol. 2015;65(2):196–206. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jacc.2014.10.034.\nLo LW, Tai CT, Lin YJ, Chang SL, Wongcharoen W, Chang SH, et al. Progressive remodeling of the atrial substrate--a novel finding from consecutive voltage mapping in patients with recurrence of atrial fibrillation after catheter ablation. J Cardiovasc Electrophysiol. 2007;18(3):258–65. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fj.1540-8167.2007.00719.x.\nSquara F, Frankel DS, Schaller R, Kapa S, Chik WW, Callans DJ, et al. Voltage mapping for delineating inexcitable dense scar in patients undergoing atrial fibrillation ablation: a new end point for enhancing pulmonary vein isolation. Heart Rhythm. 2014;11(11):1904–11. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.hrthm.2014.07.027.\nKapa S, Desjardins B, Callans DJ, Marchlinski FE, Dixit S. Contact electroanatomic mapping derived voltage criteria for characterizing left atrial scar in patients undergoing ablation for atrial fibrillation. J Cardiovasc Electrophysiol. 2014;25(10):1044–52. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fjce.12452.\nWilliams SE, Linton N, O'Neill L, Harrison J, Whitaker J, Mukherjee R, et al. The effect of activation rate on left atrial bipolar voltage in patients with paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol. 2017;28(9):1028–36. https:\u002F\u002Fdoi.org\u002F10.1111\u002Fjce.13282.\nSasaki N, Watanabe I, Okumura Y, Nagashima K, Kogawa R, Sonoda K, et al. Complex fractionated atrial electrograms, high dominant frequency regions, and left atrial voltages during sinus rhythm and atrial fibrillation. J Arrhythm. 2017;33(3):185–91. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.joa.2016.10.001.",{"VOID":1444},"10.1007\u002Fs11936-020-00833-x","2024-06-26T01:00:05.499+00:00","https:\u002F\u002Flink.springer.com\u002F10.1007\u002Fs11936-020-00833-x",[1448,1463],{"id":1449,"sortIndex":21,"researcher":20,"roles":1450,"affiliations":1451,"properties":1460,"displayName":1462,"givenName":20,"familyName":20},"4693a77d-8044-47b3-b1c4-d70ca725768b",[716],[1452],{"id":1453,"sortIndex":21,"affiliation":1454,"properties":20},"af6d8cde-0300-4b28-816f-8f180bd1bcfb",{"id":1453,"createTime":20,"updateTime":20,"relativeEntities":1455,"slug":20,"properties":1456,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1459,"statistic":20},[],{"title":1457},{"VI":1458},"Cardiology Division, Sarver Heart Center, University of Arizona, Tucson, USA",[],{"title":1461},{"VI":1462},"Bishnu P. Dhakal",{"id":1464,"sortIndex":219,"researcher":20,"roles":1465,"affiliations":1466,"properties":1475,"displayName":1477,"givenName":20,"familyName":20},"f00e9293-10da-4b96-8ffe-ebe26d0da75e",[716],[1467],{"id":1468,"sortIndex":21,"affiliation":1469,"properties":20},"b64be12f-f3c4-4ff7-85c8-9d24817c6b19",{"id":1468,"createTime":20,"updateTime":20,"relativeEntities":1470,"slug":20,"properties":1471,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1474,"statistic":20},[],{"title":1472},{"VI":1473},"Cardiac Electrophysiology Program, Sarver Heart Center, University of Arizona College of Medicine – Tucson, Tucson, USA",[],{"title":1476},{"VI":1477},"Mathew D. Hutchinson",{"url":1446,"publisher":1479,"properties":1521},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1480,"slug":10,"properties":1481,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":1485,"manageAffiliations":1490,"indexDatabases":1501,"url":20,"thumbnailPath":20,"statistic":1516,"gsStatistic":20,"type":20,"analyzePriority":20},[],{"issn":1482,"title":1483,"eissn":1484},{"VOID":13},{"EN":15},{"VOID":17},[1486],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":1487,"label":1488,"description":1489,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},[1491,1496],{"id":31,"createTime":20,"updateTime":20,"relativeEntities":1492,"slug":20,"properties":1493,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1495,"statistic":20},[],{"title":1494},{"EN":35},[37],{"id":39,"createTime":20,"updateTime":20,"relativeEntities":1497,"slug":20,"properties":1498,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1500,"statistic":20},[],{"title":1499},{"EN":43},[],[1502,1509],{"id":47,"indexDatabase":1503,"url":58,"indexYears":59,"academicFieldIds":1508,"indexDatabaseRanking":62},{"id":49,"createTime":20,"updateTime":20,"relativeEntities":1504,"label":1505,"description":1506,"key":55,"publicationTags":1507,"standard":20},[],{"EN":52,"VI":52},{"EN":52,"VI":54},[57],[61],{"id":64,"indexDatabase":1510,"url":77,"indexYears":20,"academicFieldIds":1515,"indexDatabaseRanking":20},{"id":66,"createTime":20,"updateTime":20,"relativeEntities":1511,"label":1512,"description":1513,"key":73,"publicationTags":1514,"standard":20},[],{"EN":69,"VI":69},{"EN":71,"VI":72},[75,76],[79],{"impactFactor":21,"impactFactorByYear":1517,"i10Index":93,"i10IndexLast5Year":94,"totalPublication":95,"totalPublicationByYear":1518,"totalCitation":121,"totalCitationByYear":1519,"totalCitationPerPublication":141,"totalCitationPerPublicationByYear":1520,"hindexLast5Year":166,"hindex":166},{"2012":82,"2013":83,"2014":83,"2015":84,"2016":85,"2017":86,"2018":87,"2019":88,"2020":89,"2021":90,"2022":91,"2023":92},{"1999":97,"2000":98,"2001":99,"2002":100,"2003":101,"2004":102,"2005":103,"2006":104,"2007":105,"2008":106,"2009":107,"2010":108,"2011":109,"2012":109,"2013":108,"2014":110,"2015":111,"2016":112,"2017":113,"2018":114,"2019":115,"2020":116,"2021":117,"2022":118,"2023":119,"2024":120},{"1999":123,"2000":109,"2001":124,"2002":125,"2003":126,"2004":127,"2005":112,"2006":128,"2007":129,"2008":130,"2009":113,"2010":131,"2011":132,"2012":133,"2013":93,"2014":134,"2015":135,"2016":136,"2017":137,"2018":113,"2019":138,"2020":97,"2021":139,"2023":140},{"1999":143,"2000":144,"2001":145,"2002":146,"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2010":154,"2011":155,"2012":156,"2013":141,"2014":157,"2015":158,"2016":159,"2017":160,"2018":161,"2019":162,"2020":163,"2021":164,"2023":165},{"pages":1522,"volume":1524},{"VOID":1523},"1-23",{"VOID":1525},"22","2020-09-02",2020,"2026-07-13T21:01:57.659+00:00",[62,75],{"id":1531,"createTime":1532,"updateTime":1533,"relativeEntities":1534,"slug":1535,"properties":1536,"entityType":190,"verifyStatus":191,"verifyTime":1546,"verifyNote":193,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":1547,"fullTextUrl":20,"authors":1548,"publicationType":248,"publisherRelationship":1564,"citationCount":20,"citationInfo":20,"publishDate":1612,"publishYear":1613,"citationAnalyzeStatus":297,"lastCitationAnalyze":1614,"indexDatabases":1615,"openAccess":20,"references":20,"isForceReanalyzing":692},"3c61b8d6-8f8f-4906-813e-423a6d03a303","2024-01-24T14:53:32.820+00:00","2026-06-24T15:10:57.697+00:00",[],"Management-of-pregnancy-in-women-with-palliated-and-unpalliated-congenital-heart-defects",{"abstract":1537,"title":1539,"gsPaper":1541,"references":1542,"doi":1544},{"EN":1538},"Medical advancements have made it possible for more women with congenital heart defects (CHDs) to carry successful pregnancies. Most CHD surgeries or interventions are palliative with persistent residua and sequelae exacerbated by the physiologic stresses of pregnancy. Preconception assessment, a tailored multidisciplinary approach during pregnancy, and a planned, elective delivery followed by careful postpartum monitoring may improve outcomes. Teratogenic medications should be stopped and changed to safer alternatives. Major hemodynamic changes in pregnancy, labor, and delivery may aggravate the underlying cardiovascular defects. Interventions or surgeries, when anticipated, should be performed before pregnancy. Antibiotic prophylaxis is indicated for nearly all palliated and unpalliated defects.",{"EN":1540},"Management of pregnancy in women with palliated and unpalliated congenital heart defects",{"VOID":185},{"VOID":1543},"Cutforth R, MacDonald CB: Heart sounds and murmurs in pregnancy. Am Heart J 1966, 71:741–747.\nHurst JW, Staton J, Hubbard D: Precordial murmurs during pregnancy and lactation. N Engl J Med 1958, 259:515–517.\nMetcalfe J, Ueland K: Maternal cardiovascular adjustments to pregnancy. Prog Cardiovasc Dis 1974, 16:363–374.\nResnik R: Can 29% cesarean delivery rate possibly be justified? Obstet Gynecol 2006, 107:752–754.\nNational Institutes of Health State-of-the-Science Conference statement: cesarean delivery on maternal request, March 27–29, 2006 [no author listed]. Obstet Gynecol 2006, 107:1386–1397.\nDeneux-Tharaux C, Carmona E, Bouvier-Colle MH, Breart G: Postpartum maternal mortality and cesarean delivery. Obstet Gynecol 2006, 108:541–548.\nRomano-Zeleka O, Hirsh R, Blieden L, et al.: The risk of congenital heart defects in offspring of individuals with congenital heart defects. Clin Genet 2001, 59:325–329.\nACOG Committee on Practice Bulletins: ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol 2007, 109:217–227.\nEddleman KA, Malone FD, Sullivan L, et al.: Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol 2006, 108:1067–1072.\nSharland G: Routine fetal cardiac screening: what are we doing and what should we do? Prenat Diagn 2004, 24:1123–1129.\nUpham M, Medoff-Cooper B: What are the responses and needs of mothers of infants diagnosed with congenital heart disease? MCN Am J Matern Child Nurs 2005, 30:24–29.\nPerloff JK, ed: The Clinical Recognition of Congenital Heart Disease, edn 5. Philadelphia: WB Saunders; 2003.\nChugh R: Caring for the adult with congenital heart disease: management of common defects. Permanente Journal 2007, 11:40–46. http:\u002F\u002Fxnet.kp.org\u002Fpermanentejournal\u002Fspring07\u002Fcaring.html. Accessed June 6, 2007.\nZuber M, Gautschi N, Oechslin E, et al.: Outcome of pregnancy in women with congenital shunt lesions. Heart 1999, 81:271–275.\nDrenthen W, Pieper PG, Roos-Hesselink JW, et al.: Non-cardiac complications during pregnancy in women with isolated congenital pulmonary valvar stenosis. Heart 2006, 92:1838–1843.\nNiwa K, Perloff JK, Bhuta SM, et al.: Structural abnormalities of the great arterial walls in congenital heart disease: light and electron microscopic analyses. Circulation 2001, 103:393–400.\nBeauchesne LM, Connolly HM, Ammash NM, et al.: Coarctation of the aorta: outcome of pregnancy. J Am Coll Cardiol 2001, 38:1728–1733.\nVriend JWJ, Drenthen W, Pieper PG, et al.: Outcome of pregnancy after repair of aortic coarctation. Eur Heart J 2005, 26:2173–2178.\nVeldtman GR, Connolly HM, Grogan M, et al.: Outcome of pregnancy in women with tetralogy of Fallot. J Am Coll Cardiol 2004, 44:174–180.\nSingh H, Bolton PJ, Oakley CM: Pregnancy after surgical correction of tetralogy of Fallot. Br Med J (Clin Res Ed) 1982, 285:168–170.\nNeumayer U, Somerville J: Outcome of pregnancies in patients with complex pulmonary atresia. Heart 1997, 78:16–21.\nConnolly HM, Warnes CA: Outcome of pregnancy in patients with complex pulmonic valve atresia. Am J Cardiol 1997, 79:519–521.\nDrenthen W, Pieper PG, Zoon N, et al.: Pregnancy after biventricular repair for pulmonary atresia with ventricular septal defect. Am J Cardiol 2006, 98:262–266.\nGatzoulis MA, Balaji S, Webber SA, et al.: Risk factors for arrhythmias and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet 2000, 356:975–981.\nKim WH, Seo JW, Kim SJ, et al.: Aortic dissection late after repair of tetralogy of Fallot. Int J Cardiol 2005, 101:515–516.\nRathi VK, Doyle M, Williams RB, et al.: Massive aortic root aneurysm and dissection in repaired tetralogy of Fallot; diagnosis by cardiac magnetic resonance imaging. Int J Cardiol 2005, 101:169–170.\nCanobbio MM, Morris CD, Graham TP, Landzberg MJ: Pregnancy outcomes after atrial repair for transposition of the great arteries. Am J Cardiol 2006, 98:668–672.\nClarkson PM, Wilson NJ, Neutze JM, et al.: Outcomes of pregnancy after the Mustard operation for transposition of the great arteries with intact ventricular septum. J Am Coll Cardiol 1994, 24:190–193.\nGenoni M, Jenni R, Hoerstrup SP, et al.: Pregnancy after atrial repair for transposition of the great arteries. Heart 1991, 81:276–277.\nGuedes A, Mercier LA, Leduc L, et al.: Impact of pregnancy on the systemic right ventricle after a Mustard operation for transposition of the great arteries. J Am Coll Cardiol 2004, 44:433–437.\nDrenthen W, Pieper PG, Ploeg M, et al.: Risk of complications during pregnancy after Senning or Mustard (atrial) repair of complete transposition of the great arteries. Eur Heart J 2005, 26:2588–2595.\nConnolly HM, Grogan M, Warnes CA, et al.: Pregnancy among women with congenitally corrected transposition of the great arteries. J Am Coll Cardiol 1999, 33:1692–1695.\nTherrien J, Barnes I, Somerville J: Outcome of pregnancy in patients with congenitally corrected transposition of the great arteries. Am J Cardiol 1999, 84:820–824.\nConnolly HM, Warnes CA: Ebstein’s anomaly: outcome of pregnancy. J Am Coll Cardiol 1994, 23:1194–1198.\nFontan F, Baudet E: Surgical repair of tricuspid atresia. Thorax 1971, 26:240–248.\nCanobbio MM, Mair DD, Ven der Velde M, et al.: Pregnancy outcomes after Fontan repair. J Am Coll Cardiol 1996, 28:763–767.\nDrenthen W, Pieper PG, van der Tuuk K, et al.: Pregnancy and delivery in women after Fontan palliation. Heart 2006, 92:1290–1294.\nGleicher N, Midwall J, Hochberger D, Jafffin H: Eisenmenger’s syndrome and pregnancy. Obstet Gynecol Surv 1979, 34:721–741.\nSiu SC, Sermer M, Colman JM, et al.: Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001, 104:515–521.\nPresbitero P, Somerville J, Stone S, et al.: Pregnancy in cyanotic heart disease. Circulation 1994, 89:2673–2676.\nWilson W, Taubert KA, Gewitz M, et al.: Prevention of infective endocarditis. Guidelines from the American Heart Association. A Guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation 2007, Apr 19; [Epub ahead of print].\nNahum GG, Uhl K, Kennedy DL: Antibiotic use in pregnancy and lactation. Obstet Gynecol 2006, 107:1120–1138.\nPocock SB, Chen KT: Inappropriate use of antibiotic prophylaxis to prevent infective endocarditis in obstetric patients. Obstet Gynecol 2006, 108:280–285.\nEllison J, Walker ID, Greer IA: Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. Br J Obstet Gynaecol 2000, 107:1116–1121.\nSadler L, McCowan L, White H, et al.: Pregnancy outcomes and cardiac complications in women with mechanical, bioprosthetic and homograft valves. BJOG 2000, 107:245–253.\nNassar AH, Hobeika EM, Abd Essamad HM, et al.: Pregnancy outcome in women with prosthetic heart valves. Am J Obstet Gynecol 2004, 191:1009–1013.\nSeshadri N, Goldhaber SZ, Elkayam U, et al.: The clinical challenge of bridging anticoagulation with low molecular-weight heparin in patients with mechanical valves: an evidence based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients. Am Heart J 2005, 150:27–34.\nBates S, Greer IA, Hirsh J, Ginsberg J: Use of antithrombotic agents during pregnancy. Chest 2004, 126(3 suppl):627S–644S.\nElefteriades JA: Natural history of thoracic aortic aneurysms: indications for surgery, and surgical versus nonsurgical risks. Ann Thorac Surg 2002, 74:S1877–S1880; discussion S1892–S1898.\nDavies RR, Goldstein LJ, Coady MA, et al.: Yearly rupture or dissection rates for dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann Thorac Surg 2002, 73:17–27; discussion 27–28.\nLobato AC, Puech-Leao P: Predictive factors for rupture of thoracoabdominal aortic aneurysm. J Vasc Surg 1998, 27:446–453.\nChugh R: Management of pregnancy in patients with congenital heart disease and systemic ventricular failure. Prog Pediatr Cardiol 2004, 19:47–60.\nWesseling J, van Driel D, Heymans HS, et al.: Coumarins during pregnancy: long term effects on growth and development in school age children. Thromb Haemost 2001, 85:609–613.\nWeitz JI: Low-molecular-weight heparins. N Engl J Med 1997, 337:688–698.\nCasele HL, Laifer SA, Woelkers DA, et al.: Changes in the pharmacokinetics of the low molecular weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999, 81:1113–1117.\nMaslovitz S, Many A, Landsberg JA, et al.: The safety of low molecular weight heparin therapy during labor. J Matern Fetal Neonatal Med 2005, 17:39–43.\nLip GYH, Beevers M, Churchill D, et al.: Effect of atenolol on birth weight. Am J Cardiol 1997, 79:1436–1438.\nLee CR, Wetzel G, Shannon K: Maternal arrhythmia management during pregnancy in patients with structural heart disease. Prog Pediatr Cardiol 2004, 19:71–82.\nCummins CO, Hazinski MF, Baskett PJF, et al.: Cardiac arrest associated with pregnancy. Circulation 2005, 112:150–153.\nBailey LB, Berry RJ: Folic acid supplementation and the occurrence of congenital heart defect, orofacial clefts, multiple births and miscarriages. Am J Clin Nutr 2005, 81(suppl):1213S–1217S.\nMiner PD: Contraceptive choices for females with congenital heart disease. Prog Pediatr Cardiol 2004, 19:15–24.",{"VOID":1545},"10.1007\u002Fs11936-007-0062-x","2024-08-30T08:09:58.887+00:00","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11936-007-0062-x",[1549],{"id":1550,"sortIndex":21,"researcher":20,"roles":1551,"affiliations":1552,"properties":1561,"displayName":1563,"givenName":20,"familyName":20},"a96172ea-93c7-4d39-9c4c-7421dd2fedbc",[716],[1553],{"id":1554,"sortIndex":21,"affiliation":1555,"properties":20},"ede9b473-8d4c-4df8-8a42-d8f41a7c3b0e",{"id":1554,"createTime":20,"updateTime":20,"relativeEntities":1556,"slug":20,"properties":1557,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1560,"statistic":20},[],{"title":1558},{"VI":1559},"Adult Congenital Heart Disease and Heart Disease in Pregnancy, Kaiser Foundation Hospitals, Department of Cardiology, Panorama City, USA",[],{"title":1562},{"VI":1563},"Reema Chugh",{"url":1547,"publisher":1565,"properties":1607},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1566,"slug":10,"properties":1567,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":1571,"manageAffiliations":1576,"indexDatabases":1587,"url":20,"thumbnailPath":20,"statistic":1602,"gsStatistic":20,"type":20,"analyzePriority":20},[],{"issn":1568,"title":1569,"eissn":1570},{"VOID":13},{"EN":15},{"VOID":17},[1572],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":1573,"label":1574,"description":1575,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},[1577,1582],{"id":31,"createTime":20,"updateTime":20,"relativeEntities":1578,"slug":20,"properties":1579,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1581,"statistic":20},[],{"title":1580},{"EN":35},[37],{"id":39,"createTime":20,"updateTime":20,"relativeEntities":1583,"slug":20,"properties":1584,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1586,"statistic":20},[],{"title":1585},{"EN":43},[],[1588,1595],{"id":47,"indexDatabase":1589,"url":58,"indexYears":59,"academicFieldIds":1594,"indexDatabaseRanking":62},{"id":49,"createTime":20,"updateTime":20,"relativeEntities":1590,"label":1591,"description":1592,"key":55,"publicationTags":1593,"standard":20},[],{"EN":52,"VI":52},{"EN":52,"VI":54},[57],[61],{"id":64,"indexDatabase":1596,"url":77,"indexYears":20,"academicFieldIds":1601,"indexDatabaseRanking":20},{"id":66,"createTime":20,"updateTime":20,"relativeEntities":1597,"label":1598,"description":1599,"key":73,"publicationTags":1600,"standard":20},[],{"EN":69,"VI":69},{"EN":71,"VI":72},[75,76],[79],{"impactFactor":21,"impactFactorByYear":1603,"i10Index":93,"i10IndexLast5Year":94,"totalPublication":95,"totalPublicationByYear":1604,"totalCitation":121,"totalCitationByYear":1605,"totalCitationPerPublication":141,"totalCitationPerPublicationByYear":1606,"hindexLast5Year":166,"hindex":166},{"2012":82,"2013":83,"2014":83,"2015":84,"2016":85,"2017":86,"2018":87,"2019":88,"2020":89,"2021":90,"2022":91,"2023":92},{"1999":97,"2000":98,"2001":99,"2002":100,"2003":101,"2004":102,"2005":103,"2006":104,"2007":105,"2008":106,"2009":107,"2010":108,"2011":109,"2012":109,"2013":108,"2014":110,"2015":111,"2016":112,"2017":113,"2018":114,"2019":115,"2020":116,"2021":117,"2022":118,"2023":119,"2024":120},{"1999":123,"2000":109,"2001":124,"2002":125,"2003":126,"2004":127,"2005":112,"2006":128,"2007":129,"2008":130,"2009":113,"2010":131,"2011":132,"2012":133,"2013":93,"2014":134,"2015":135,"2016":136,"2017":137,"2018":113,"2019":138,"2020":97,"2021":139,"2023":140},{"1999":143,"2000":144,"2001":145,"2002":146,"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2010":154,"2011":155,"2012":156,"2013":141,"2014":157,"2015":158,"2016":159,"2017":160,"2018":161,"2019":162,"2020":163,"2021":164,"2023":165},{"pages":1608,"volume":1610},{"VOID":1609},"414-427",{"VOID":1611},"9","2008-03-18",2008,"2026-06-24T15:10:57.695+00:00",[62,75],{"id":1617,"createTime":1618,"updateTime":1619,"relativeEntities":1620,"slug":1621,"properties":1622,"entityType":190,"verifyStatus":191,"verifyTime":1633,"verifyNote":193,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":1634,"fullTextUrl":20,"authors":1635,"publicationType":248,"publisherRelationship":1679,"citationCount":20,"citationInfo":20,"publishDate":1727,"publishYear":1728,"citationAnalyzeStatus":19,"lastCitationAnalyze":1729,"indexDatabases":1730,"openAccess":20,"references":20,"isForceReanalyzing":692},"37434745-c567-434d-8115-159252cda2b8","2024-01-30T01:33:51.293+00:00","2026-05-19T11:18:47.796+00:00",[],"Peripartum-Cardiomyopathy-a-Review-for-the-Clinician",{"abstract":1623,"title":1625,"gsPaper":1627,"references":1629,"doi":1631},{"EN":1624},"This review summarizes the pathophysiology, diagnosis, and treatment of peripartum cardiomyopathy (PPCM), with a focus on recent discoveries of clinical relevance. An increase in oxidative stress and anti-angiogenic activity play key roles in the pathophysiology of peripartum cardiomyopathy. Therapies that target this dysregulation may have a future role in treatment. Suppression of prolactin release using bromocriptine, a dopamine-receptor antagonist, has been associated with more favorable outcomes in small studies but more research is needed. Similarly, VEGF agonists may prove to be a novel therapy by upregulating angiogenesis. Peripartum cardimyopathy typically presents in the third trimester or in first few months postpartum. Both genetic and clinical risk factors for PPCM have been identified. Women with PPCM should be managed by a multidisciplinary team with experience in high risk pregnancy and the treatment of heart failure. These women benefit from the use of standard treatments for heart failure therapy with the exception of avoiding ACE inhibitors and ARBs while pregnant. While the rate of recovery of ventricular function in PPCM is higher than in other forms of dilated cardiomyopathy, mechanical circulatory support and\u002For cardiac transplantation are required in some cases.",{"EN":1626},"Peripartum Cardiomyopathy: a Review for the Clinician",{"VOID":1628},"[\"17571050725159279986\"]",{"VOID":1630},"Arany Z, Elkayam U. Peripartum cardiomyopathy. Circulation. 2016;133(14):1397–409. https:\u002F\u002Fdoi.org\u002F10.1161\u002FCIRCULATIONAHA.115.020491.\nFett JD, Christie LG, Carraway RD, Ansari AA, Sundstrom JB, Murphy JG. Unrecognized peripartum cardiomyopathy in Haitian women. Int J Gynaecol Obstet. 2005;90(2):161–6. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ijgo.2005.05.004.\nDesai D, Moodley J, Naidoo D. Peripartum cardiomyopathy: experiences at King Edward VIII Hospital, Durban, South Africa and a review of the literature. Trop Dr. 1995;25(3):118–23. https:\u002F\u002Fdoi.org\u002F10.1177\u002F004947559502500310.\nBrar SS, Khan SS, Sandhu GK, Jorgensen MB, Parikh N, Hsu JW, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol. 2007;100(2):302–4. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.amjcard.2007.02.092.\nErsboll AS, Johansen M, Damm P, Rasmussen S, Vejlstrup NG, Gustafsson F. Peripartum cardiomyopathy in Denmark: a retrospective, population-based study of incidence, management and outcome. Eur J Heart Fail. 2017;19(12):1712–20. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fejhf.882.\nHilfiker-Kleiner D, Sliwa K. Pathophysiology and epidemiology of peripartum cardiomyopathy. Nat Rev Cardiol. 2014;11(6):364–70. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnrcardio.2014.37.\n• Ware JS, Li J, Mazaika E, Yasso CM, DeSouza T, Cappola TP, et al. Shared genetic predisposition in peripartum and dilated cardiomyopathies. N Engl J Med. 2016;374(3):233–41. https:\u002F\u002Fdoi.org\u002F10.1056\u002FNEJMoa1505517. The authors sequenced 43 genes which are known to be associated with dilated cardiomyopathy in a population of women with PPCM. They found a similar distribution of truncating variants, suggesting that a common genetic predisposition may underlie both disorders.\nvan Spaendonck-Zwarts KY, Posafalvi A, van den Berg MP, Hilfiker-Kleiner D, Bollen IA, Sliwa K, et al. Titin gene mutations are common in families with both peripartum cardiomyopathy and dilated cardiomyopathy. Eur Heart J. 2014;35(32):2165–73. https:\u002F\u002Fdoi.org\u002F10.1093\u002Feurheartj\u002Fehu050.\nHalkein J, Tabruyn SP, Ricke-Hoch M, Haghikia A, Nguyen NQ, Scherr M, et al. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy. J Clin Invest. 2013;123(5):2143–54. https:\u002F\u002Fdoi.org\u002F10.1172\u002FJCI64365.\nPatten IS, Rana S, Shahul S, Rowe GC, Jang C, Liu L, et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012;485(7398):333–8. https:\u002F\u002Fdoi.org\u002F10.1038\u002Fnature11040.\n• McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, et al. Clinical outcomes for peripartum cardiomyopathy in North America: results of the IPAC study (Investigations of Pregnancy-Associated Cardiomyopathy). J Am Coll Cardiol. 2015;66(8):905–14. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jacc.2015.06.1309.Multicenter US-based study which that most women with PPCM recover LV function. Thisteen percent of women in this study had a major event or persistent severe cardiomyopathy at 1 year.\nSliwa K, Skudicky D, Bergemann A, Candy G, Puren A, Sareli P. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas\u002FAPO-1. J Am Coll Cardiol. 2000;35(3):701–5.\nIrizarry OC, Levine LD, Lewey J, Boyer T, Riis V, Elovitz MA, et al. Comparison of clinical characteristics and outcomes of peripartum cardiomyopathy between African American and non-African American women. JAMA Cardiol. 2017;2(11):1256–60. https:\u002F\u002Fdoi.org\u002F10.1001\u002Fjamacardio.2017.3574.\nSliwa K, Mebazaa A, Hilfiker-Kleiner D, Petrie MC, Maggioni AP, Laroche C et al. Clinical characteristics of patients from the worldwide registry on peripartum cardiomyopathy (PPCM): EURObservational Research Programme in conjunction with the Heart Failure Association of the European Society of Cardiology Study Group on PPCM. Eur J Heart Fail. 2017;19(9):1131–1141. doi:https:\u002F\u002Fdoi.org\u002F10.1002\u002Fejhf.780. Description of the baseline clinical and echocardiographic characteristics of women enrolled in this multicenter registry.\nHu CL, Li YB, Zou YG, Zhang JM, Chen JB, Liu J, et al. Troponin T measurement can predict persistent left ventricular dysfunction in peripartum cardiomyopathy. Heart. 2007;93(4):488–90. https:\u002F\u002Fdoi.org\u002F10.1136\u002Fhrt.2006.087387.\nBlauwet LA, Delgado-Montero A, Ryo K, Marek JJ, Alharethi R, Mather PJ et al. Right ventricular function in peripartum cardiomyopathy at presentation is associated with subsequent left ventricular recovery and clinical outcomes. Circ Heart Fail. 2016;9(5). doi:https:\u002F\u002Fdoi.org\u002F10.1161\u002FCIRCHEARTFAILURE.115.002756.\nSafirstein JG, Ro AS, Grandhi S, Wang L, Fett JD, Staniloae C. Predictors of left ventricular recovery in a cohort of peripartum cardiomyopathy patients recruited via the internet. Int J Cardiol. 2012;154(1):27–31. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ijcard.2010.08.065.\nElkayam U. Risk of subsequent pregnancy in women with a history of peripartum cardiomyopathy. J Am Coll Cardiol. 2014;64(15):1629–36. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jacc.2014.07.961.\nYancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF\u002FAHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\u002FAmerican Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147–239. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jacc.2013.05.019.\nTriebel J, Clapp C, de la Martinez EG, Bertsch T. Remarks on the prolactin hypothesis of peripartum cardiomyopathy. Front Endocrinol (Lausanne). 2017;8:77. https:\u002F\u002Fdoi.org\u002F10.3389\u002Ffendo.2017.00077.\nLydakis C, Lip GY, Beevers M, Beevers DG. Atenolol and fetal growth in pregnancies complicated by hypertension. Am J Hypertens. 1999;12(6):541–7.\nTanaka K, Tanaka H, Kamiya C, Katsuragi S, Sawada M, Tsuritani M, et al. Beta-blockers and fetal growth restriction in pregnant women with cardiovascular disease. Circ J. 2016;80(10):2221–6. https:\u002F\u002Fdoi.org\u002F10.1253\u002Fcircj.CJ-15-0617.\nTaylor J. The first ESC Guidelines on the management of cardiovascular diseases during pregnancy. Eur Heart J. 2011;32(24):3055–6. https:\u002F\u002Fdoi.org\u002F10.1093\u002Feurheartj\u002Fehr235.\n• Bauersachs J, Arrigo M, Hilfiker-Kleiner D, Veltmann C, Coats AJ, Crespo-Leiro MG, et al. Current management of patients with severe acute peripartum cardiomyopathy: practical guidance from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail. 2016;18(9):1096–105. https:\u002F\u002Fdoi.org\u002F10.1002\u002Fejhf.586. Comprehensive guidelines regarding the management of women with PPCM, including critical care management.\nHilfiker-Kleiner D, Haghikia A, Berliner D, Vogel-Claussen J, Schwab J, Franke A, et al. Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study. Eur Heart J. 2017;38(35):2671–9. https:\u002F\u002Fdoi.org\u002F10.1093\u002Feurheartj\u002Fehx355.\nMallikethi-Reddy S, Akintoye E, Trehan N, Sharma S, Briasoulis A, Jagadeesh K, et al. Burden of arrhythmias in peripartum cardiomyopathy: analysis of 9841 hospitalizations. Int J Cardiol. 2017;235:114–7. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.ijcard.2017.02.084.\nPillarisetti J, Kondur A, Alani A, Reddy M, Reddy M, Vacek J, et al. Peripartum cardiomyopathy: predictors of recovery and current state of implantable cardioverter-defibrillator use. J Am Coll Cardiol. 2014;63(25 Pt A):2831–9. https:\u002F\u002Fdoi.org\u002F10.1016\u002Fj.jacc.2014.04.014.",{"VOID":1632},"10.1007\u002Fs11936-018-0690-3","2024-06-24T01:49:43.761+00:00","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11936-018-0690-3",[1636,1651,1666],{"id":1637,"sortIndex":21,"researcher":20,"roles":1638,"affiliations":1639,"properties":1648,"displayName":1650,"givenName":20,"familyName":20},"f1d9b947-b71f-4c29-baf6-c19ca37b3072",[716],[1640],{"id":1641,"sortIndex":21,"affiliation":1642,"properties":20},"458d08dd-f82e-445a-a121-b623eef520b5",{"id":1641,"createTime":20,"updateTime":20,"relativeEntities":1643,"slug":20,"properties":1644,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1647,"statistic":20},[],{"title":1645},{"VI":1646},"Knight Cardiovascular Institute, Oregon Health and Sciences University, Portland, USA",[],{"title":1649},{"VI":1650},"Abigail Khan",{"id":1652,"sortIndex":219,"researcher":20,"roles":1653,"affiliations":1654,"properties":1663,"displayName":1665,"givenName":20,"familyName":20},"f514c242-f984-49f4-b489-d1acaf978e88",[716],[1655],{"id":1656,"sortIndex":21,"affiliation":1657,"properties":20},"1705d565-1aea-4b41-abd0-5fc259ddaa8e",{"id":1656,"createTime":20,"updateTime":20,"relativeEntities":1658,"slug":20,"properties":1659,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1662,"statistic":20},[],{"title":1660},{"VI":1661},"Department of Obstetrics and Gynecology, Oregon Health and Sciences University, Portland, USA",[],{"title":1664},{"VI":1665},"Emmanuelle Paré",{"id":1667,"sortIndex":140,"researcher":20,"roles":1668,"affiliations":1669,"properties":1676,"displayName":1678,"givenName":20,"familyName":20},"1d8ad8f6-8413-4d26-b58c-fc92317bc261",[716],[1670],{"id":1641,"sortIndex":21,"affiliation":1671,"properties":20},{"id":1641,"createTime":20,"updateTime":20,"relativeEntities":1672,"slug":20,"properties":1673,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1675,"statistic":20},[],{"title":1674},{"VI":1646},[],{"title":1677},{"VI":1678},"Shimoli Shah",{"url":1634,"publisher":1680,"properties":1722},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1681,"slug":10,"properties":1682,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":1686,"manageAffiliations":1691,"indexDatabases":1702,"url":20,"thumbnailPath":20,"statistic":1717,"gsStatistic":20,"type":20,"analyzePriority":20},[],{"issn":1683,"title":1684,"eissn":1685},{"VOID":13},{"EN":15},{"VOID":17},[1687],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":1688,"label":1689,"description":1690,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},[1692,1697],{"id":31,"createTime":20,"updateTime":20,"relativeEntities":1693,"slug":20,"properties":1694,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1696,"statistic":20},[],{"title":1695},{"EN":35},[37],{"id":39,"createTime":20,"updateTime":20,"relativeEntities":1698,"slug":20,"properties":1699,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1701,"statistic":20},[],{"title":1700},{"EN":43},[],[1703,1710],{"id":47,"indexDatabase":1704,"url":58,"indexYears":59,"academicFieldIds":1709,"indexDatabaseRanking":62},{"id":49,"createTime":20,"updateTime":20,"relativeEntities":1705,"label":1706,"description":1707,"key":55,"publicationTags":1708,"standard":20},[],{"EN":52,"VI":52},{"EN":52,"VI":54},[57],[61],{"id":64,"indexDatabase":1711,"url":77,"indexYears":20,"academicFieldIds":1716,"indexDatabaseRanking":20},{"id":66,"createTime":20,"updateTime":20,"relativeEntities":1712,"label":1713,"description":1714,"key":73,"publicationTags":1715,"standard":20},[],{"EN":69,"VI":69},{"EN":71,"VI":72},[75,76],[79],{"impactFactor":21,"impactFactorByYear":1718,"i10Index":93,"i10IndexLast5Year":94,"totalPublication":95,"totalPublicationByYear":1719,"totalCitation":121,"totalCitationByYear":1720,"totalCitationPerPublication":141,"totalCitationPerPublicationByYear":1721,"hindexLast5Year":166,"hindex":166},{"2012":82,"2013":83,"2014":83,"2015":84,"2016":85,"2017":86,"2018":87,"2019":88,"2020":89,"2021":90,"2022":91,"2023":92},{"1999":97,"2000":98,"2001":99,"2002":100,"2003":101,"2004":102,"2005":103,"2006":104,"2007":105,"2008":106,"2009":107,"2010":108,"2011":109,"2012":109,"2013":108,"2014":110,"2015":111,"2016":112,"2017":113,"2018":114,"2019":115,"2020":116,"2021":117,"2022":118,"2023":119,"2024":120},{"1999":123,"2000":109,"2001":124,"2002":125,"2003":126,"2004":127,"2005":112,"2006":128,"2007":129,"2008":130,"2009":113,"2010":131,"2011":132,"2012":133,"2013":93,"2014":134,"2015":135,"2016":136,"2017":137,"2018":113,"2019":138,"2020":97,"2021":139,"2023":140},{"1999":143,"2000":144,"2001":145,"2002":146,"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2010":154,"2011":155,"2012":156,"2013":141,"2014":157,"2015":158,"2016":159,"2017":160,"2018":161,"2019":162,"2020":163,"2021":164,"2023":165},{"pages":1723,"volume":1725},{"VOID":1724},"1-9",{"VOID":1726},"20","2018-09-29",2018,"2026-05-19T11:18:47.794+00:00",[62,75],{"id":1732,"createTime":1733,"updateTime":1734,"relativeEntities":1735,"slug":1736,"properties":1737,"entityType":190,"verifyStatus":191,"verifyTime":1747,"verifyNote":193,"languages":20,"translateLanguages":20,"viewCount":21,"primaryUrl":1748,"fullTextUrl":20,"authors":1749,"publicationType":248,"publisherRelationship":1778,"citationCount":21,"citationInfo":1826,"publishDate":1829,"publishYear":1827,"citationAnalyzeStatus":19,"lastCitationAnalyze":1734,"indexDatabases":1830,"openAccess":20,"references":20,"isForceReanalyzing":692},"b8b7960d-4a0b-42f3-80ef-5f68a8f4349a","2024-01-29T14:04:39.528+00:00","2026-05-18T04:49:18.606+00:00",[],"Myocarditis",{"abstract":1738,"title":1740,"gsPaper":1741,"references":1743,"doi":1745},{"EN":1739},"Myocarditis and its sequela, dilated cardiomyopathy (DCM), cause substantial morbidity and mortality, especially in children and young adults. Physicians should include myocarditis in the differential diagnosis of all patients who have new symptoms of heart failure, arrhythmia, or chest pain syndromes of unclear cause, and should strongly consider performing endomyocardial biopsy (EMB) to establish the diagnosis. It may be necessary to perform multiple or serial biopsies to increase sensitivity. Patients with myocarditis and symptomatic heart failure, chest pain, or arrhythmias need hospitalization for evaluation and treatment. Patients with symptomatic left ventricular dysfunction should be treated with conventional heart failure therapy, including angiotensin-converting enzyme (ACE) inhibitors, digitalis, diuretics, and β-blockers. Patients with arrhythmias or syncope may require electrophysiologic evaluation. In addition to conventional therapy, physicians should consider a course of immunosuppressive therapy in selected patients. The clinical course, response to therapy, and left ventricular function need close monitoring. Patients with myocarditis and rapidly progressive heart failure or cardiogenic shock should be referred early to an advanced heart failure center for implantation of a ventricular assist device and consideration for cardiac transplantation.",{"EN":1736},{"VOID":1742},"[\"15400455080437664650\",\"9375613818792647464\"]",{"VOID":1744},"Baboonian C, Davies MJ, Booth JC, et al.: Coxsackie B viruses and human heart disease. Curr Top Microbiol Immunol 1997, 223:31–52.\nWhy H, Meany T, Richardson P, et al.: Clinical and prognostic significance of detection of enteroviral RNA in the myocardium of patients with myocarditis or dilated cardiomyopathy. Circulation 1994, 89:2582–2589.\nGrogan M, Redfield MM, Bailer KR, et al.: Long-term outcome of patients with biopsy-proven myocarditis: comparison with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 1995, 26:80–84.\nCaforio ALP, Goldman JH, Haven AJ, et al.: Evidence for autoimmunity to myosin and other heart-specific autoantigens in patients with dilated cardiomyopathy and their relatives. Int J Cardiol 1996, 54:157–163.\nLauer B, Schannwell M, Kuhl U, et al.: Antimyosin antibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 2000, 35:11–18.\nMcNamara DM, Starling RC, Dec W, et al., for the IMAC investigators: Prevalence of myocarditis in acute dilated cardiomyopathy. Congest Heart Fail 1999, 5:54.\nFelker GM, Thompson RE, Hare JM, et al.: Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000, 342:1077–1084.\nMcCarthy RE III, Hruban RH, Kasper EK: Association between the incidence of histopathologic myocarditis and non-polio enterovirus isolates in the United States. Paper presented at the 71st Scientific Session of the American Heart Association, Dallas, TX, November 8–11, 1998.\nHuber SA, Gauntt CJ, Sakkinen P: Enteroviruses and myocarditis: viral pathogenesis through replication, cytokine induction and immunopathogenicity. Adv Virus Res 1998, 51:35–80. Excellent review article detailing pathogenic mechanisms of myocarditis and DCM.\nWessely R, Klingel K, Santana LF, et al.: Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitationcontraction coupling and dilated cardiomyopathy. J Clin Invest 1998, 102:1444–1453.\nBowles NE, Towbin JA: Molecular aspects of myocarditis. Curr Opin Cardiol 1998, 13:179–184.\nWoodruff JF, Woodruff JJ: Involvement of T lymphocytes in the pathogenesis of Coxsackie virus B3 heart disease. J Immunol 1974, 113:1726–1734.\nAretz HT, Billingham ME, Edwards WB, et al.: Myocarditis. A histopathologic definition and classification. Cardiovasc Pathol 1987, 1:3–14.\nMcCarthy RE, Boehmer JP, Hruban RH, et al.: Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 2000, 342:690–695.\nWinkel E, Costanzo MR: Chronic heart failure. Curr Treat Options Cardiovasc Med 1999, 1:231–241.\nMaisch B, Herzum M, Hufnagel G, et al.: Immunosuppressive and immunomodulatory treatment for myocarditis. Curr Opin Cardiol 1996, 11:310–324.\nFriman G, Illback NG: Acute infection: metabolic responses, effects on performance, interaction with exercise, and myocarditis. Int J Sports Med 1998, 19(suppl 3):S172-S182.\nParrillo JE, Cunnion RE, Epstein SE, et al.: A prospective, randomized, controlled trial of prednisone for dilated cardiomyopathy. N Engl J Med 1989, 321:1061–1068. First major controlled trial of immunosuppressive therapy to treat inflammatory cardiomyopathy. A 3-month course of prednisone therapy improved LV function in an inflammatory or reactive form of DCM.\nLatham RD, Mulrow JP, Virmani R, et al.: Incidence of myocarditis and efficacy of prednisone therapy. Am Heart J 1989, 117:876–881.\nMason JW, O’Connell JB, Herskowitz A, et al.: A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995, 333:269–275.\nWojnicz R, Nowalany-Kozielska E, Wojciechowska C, et al.: Randomized, placebo-controlled study for immunosuppressive treatment of inflammatory dilated cardiomyopathy. Two-year follow-up results. Circulation 2001, 104:39–45.\nParrillo JE: Myocarditis: how should we treat in 1998? J Heart Lung Transplant 1998, 17:941–944.\nDrucker NA, Colan SD, Lewis AB, et al.: Globulin treatment of acute myocarditis in the pediatric population. Circulation 1994, 89:252–257.\nMcNamara DM, Rosenblum WD, Janosko KM, et al.: Intravenous immune globulin in the therapy of myocarditis and acute cardiomyopathy. Circulation 1997, 95:2476–2478.\nMcNamara DM, Holubkov R, Starling RC, et al.: Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001, 103:2254–2259. First large controlled, randomized trial of immune globulin to treat myocarditis in adults. It showed no benefit.\nStille-Siegener M, Heim A, Figulla HR: Subclassification of dilated cardiomyopathy and interferon treatment. Eur Heart J 1995, 16(suppl O):147–149.\nMiric M, Miskovic A, Brkic S: Long-term follow-up of patients with myocarditis and idiopathic dilated cardiomyopathy after immunomodulatory therapy. FEMS Immunol Med Microbiol 1994, 10:65–74.\nZhang H, Soteriou B, Knowlson S, et al.: Characterisation of genomic RNA of coxsackie B3 in murine myocarditis: reliability of direct sequencing of reverse transcription-nested polymerase chain reaction products. J Virol Methods 1997, 69:7–17.\nNi J, Bowles NE, Kim YH, et al.: Viral infection of the myocardium in endocardial fibroelastosis. Molecular evidence for the role of mumps virus as an etiologic agent. Circulation 1997, 95:133–139.",{"VOID":1746},"10.1007\u002Fs11936-002-0040-2","2024-05-15T23:24:03.813+00:00","https:\u002F\u002Flink.springer.com\u002Farticle\u002F10.1007\u002Fs11936-002-0040-2",[1750,1765],{"id":1751,"sortIndex":21,"researcher":20,"roles":1752,"affiliations":1753,"properties":1762,"displayName":1764,"givenName":20,"familyName":20},"663dc6d1-16ff-4a5f-a6fb-78df717f7312",[716],[1754],{"id":1755,"sortIndex":21,"affiliation":1756,"properties":20},"5e248370-fa84-46d9-9c12-d66d2dd96568",{"id":1755,"createTime":20,"updateTime":20,"relativeEntities":1757,"slug":20,"properties":1758,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1761,"statistic":20},[],{"title":1759},{"VI":1760},"Mainline Heart Failure and Transplant Program, Wynnewood, USA",[],{"title":1763},{"VI":1764},"Elaine Winkel",{"id":1766,"sortIndex":219,"researcher":20,"roles":1767,"affiliations":1768,"properties":1775,"displayName":1777,"givenName":20,"familyName":20},"d10e4eda-7365-4979-9783-83a71bd9d739",[716],[1769],{"id":1755,"sortIndex":21,"affiliation":1770,"properties":20},{"id":1755,"createTime":20,"updateTime":20,"relativeEntities":1771,"slug":20,"properties":1772,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1774,"statistic":20},[],{"title":1773},{"VI":1760},[],{"title":1776},{"VI":1777},"Joseph Parrillo",{"url":1748,"publisher":1779,"properties":1821},{"id":6,"createTime":7,"updateTime":8,"relativeEntities":1780,"slug":10,"properties":1781,"entityType":18,"verifyStatus":19,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":21,"subjectFields":1785,"manageAffiliations":1790,"indexDatabases":1801,"url":20,"thumbnailPath":20,"statistic":1816,"gsStatistic":20,"type":20,"analyzePriority":20},[],{"issn":1782,"title":1783,"eissn":1784},{"VOID":13},{"EN":15},{"VOID":17},[1786],{"id":24,"createTime":20,"updateTime":20,"relativeEntities":1787,"label":1788,"description":1789,"parentId":20,"standard":20,"scholarHubFieldId":20},[],{"EN":27},{},[1791,1796],{"id":31,"createTime":20,"updateTime":20,"relativeEntities":1792,"slug":20,"properties":1793,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1795,"statistic":20},[],{"title":1794},{"EN":35},[37],{"id":39,"createTime":20,"updateTime":20,"relativeEntities":1797,"slug":20,"properties":1798,"entityType":20,"verifyStatus":20,"verifyTime":20,"verifyNote":20,"languages":20,"translateLanguages":20,"viewCount":20,"url":20,"parentIds":1800,"statistic":20},[],{"title":1799},{"EN":43},[],[1802,1809],{"id":47,"indexDatabase":1803,"url":58,"indexYears":59,"academicFieldIds":1808,"indexDatabaseRanking":62},{"id":49,"createTime":20,"updateTime":20,"relativeEntities":1804,"label":1805,"description":1806,"key":55,"publicationTags":1807,"standard":20},[],{"EN":52,"VI":52},{"EN":52,"VI":54},[57],[61],{"id":64,"indexDatabase":1810,"url":77,"indexYears":20,"academicFieldIds":1815,"indexDatabaseRanking":20},{"id":66,"createTime":20,"updateTime":20,"relativeEntities":1811,"label":1812,"description":1813,"key":73,"publicationTags":1814,"standard":20},[],{"EN":69,"VI":69},{"EN":71,"VI":72},[75,76],[79],{"impactFactor":21,"impactFactorByYear":1817,"i10Index":93,"i10IndexLast5Year":94,"totalPublication":95,"totalPublicationByYear":1818,"totalCitation":121,"totalCitationByYear":1819,"totalCitationPerPublication":141,"totalCitationPerPublicationByYear":1820,"hindexLast5Year":166,"hindex":166},{"2012":82,"2013":83,"2014":83,"2015":84,"2016":85,"2017":86,"2018":87,"2019":88,"2020":89,"2021":90,"2022":91,"2023":92},{"1999":97,"2000":98,"2001":99,"2002":100,"2003":101,"2004":102,"2005":103,"2006":104,"2007":105,"2008":106,"2009":107,"2010":108,"2011":109,"2012":109,"2013":108,"2014":110,"2015":111,"2016":112,"2017":113,"2018":114,"2019":115,"2020":116,"2021":117,"2022":118,"2023":119,"2024":120},{"1999":123,"2000":109,"2001":124,"2002":125,"2003":126,"2004":127,"2005":112,"2006":128,"2007":129,"2008":130,"2009":113,"2010":131,"2011":132,"2012":133,"2013":93,"2014":134,"2015":135,"2016":136,"2017":137,"2018":113,"2019":138,"2020":97,"2021":139,"2023":140},{"1999":143,"2000":144,"2001":145,"2002":146,"2003":147,"2004":148,"2005":149,"2006":150,"2007":151,"2008":152,"2009":153,"2010":154,"2011":155,"2012":156,"2013":141,"2014":157,"2015":158,"2016":159,"2017":160,"2018":161,"2019":162,"2020":163,"2021":164,"2023":165},{"pages":1822,"volume":1824},{"VOID":1823},"455-466",{"VOID":1825},"4",{"total":21,"publishYear":1827,"statisticByYear":1828},2002,{},"2002-11-01",[62,75]]